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ABSTRACT 
 
NEAR-IR ABSORBING BODIPY FUNCTIONALIZED SPIONs: A 
POTENTIAL MAGNETIC NANOPLATFORM FOR DIAGNOSIS AND 
THERAPY  
 
Elif Ertem 
 
 
M.S. in Materials Science and Nanotechnology 
Supervisor: Prof. Dr. Engin U. Akkaya 
July, 2012 
 
Photodynamic therapy (PDT), especially with the recent advances in 
photosensitizer design has already been established as a noninvasive technique for 
cancer treatment. In PDT, photosensitizers (PSs) are targeted to tumor sites either 
actively or passively, and are irradiated with a laser of appropriate wavelength. 
The stimulated PSs transfer excitation energy to endogenous oxygen converting it 
to reactive oxygen species (ROS) that can kill tumor cells. Up to now, numerous 
nanomaterials tailored to suitable size, have been studied for effective delivery of 
PSs. Recently, Near IR-based absorbing nanomaterials which have a rising 
potency to implement light-triggered tumor ablation have attracted much attention 
since near-IR light in the 650–850 nm range penetrates more deeply in tissues. In 
addition, imaging of these nanomaterials carrying PSs is very important in order 
to prevent damage to the healthy tissues upon irradiation. Magnetic resonance 
imaging (MRI) is a powerful technique due to its excellent spatial resolution and 
depth for in vivo imaging. In this study, a multidisciplinary approach was utilized 
to create MRI active, near IR-based functional nanomaterials. This approach 
involves (i) nanochemistry to prepare silica coated super paramagnetic iron oxide 
(core-shell) nanoparticles, (ii) organic chemistry to synthesize four different type 
of near- IR absorbing Bodipy derivatives as PSs, and (iii) spectroscopy to verify 
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singlet oxygen production. Four different type of Bodipy based PSs were 
covalently attached to MRI active, biocompatible, and nontoxic nanocarriers and 
generation of singlet oxygen capabilities were evaluated. It was demonstrated that 
these core-shell nanoparticles are promising delivery vehicles of PSs for the use in 
diagnosis and therapy. 
 
 
Keywords: Bodipy, photodynamic therapy, photosensitizer, magnetic resonance 
imaging, super paramagnetic iron oxide nanoparticle, core-shell nanoparticle 
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ÖZET 
 
YAKIN KIZIL ÖTESİ BÖLGEDE ABSORBE EDEN BODIPY TÜREVLERİ 
İLE FONKSİYONLANDIRILMIŞ SÜPER PARAMANYETİK DEMİR OKSİT 
NANOPARÇACIKLARI: TANI VE TERAPİ İÇİN POTANSİYEL MANYETİK 
NANOPLATFORM 
 
 
 
Elif Ertem 
Malzeme Bilimi ve Nanoteknoloji Programı, Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Engin U. Akkaya 
Temmuz, 2012 
 
 
Fotodinamik terapi, fotoduyarlaştırıcılarda süregelen gelişmelerle birlikte, kanser 
tedavisinde çoktan yerleşmiş invazif olmayan bir tedavi yöntemidir. Fotodinamik 
terapide, fotoduyarlaştırıcıya tümörlü bölgeler aktif veya pasif olarak hedefletilir 
ve lazer ile uyarılır. Uyarılmış fotoduyarlaştırıcılar enerjisini içerdeki oksijene 
transfer eder, oksijen o enerjiyi tümör hücrelerini öldüren reaktif oksijen türlerine 
dönüştürür. Şimdiye kadar, uygun boyuta ayarlanmış çok sayıda nanomaddenin 
fotoduyarlaştırıcıları verimli bir şekilde hedefe ulaştırdıkları gösterilmiştir. Son 
zamanlarda, ışık uyarısıyla tümör yokedilmesi uygulamalarında yükselen bir 
potansiyele sahip olduğu için yakın kızıl ötesi bölgesi temelli nanomalzemeler 
büyük ölçüde ilgi toplamıştır. Çünkü 650–850 nm arası olan yakın kızıl ötesi ışık 
deride çok daha derinlere ilerleyebilmektedir. Ek olarak, fotoduyarlaştırıcıları 
taşıyan nanomateryallari görüntülemek uyarma esnasında sağlıklı deriye zarar 
vermeme açısından çok önemlidir. Manyetik rezonans görüntülemesi (MRI) canlı 
görüntülemesindeki mükemmel uzaysal çözünürlüğü ve derinliği açısından çok 
güçlü bir tekniktir. Bu çalışmada, MRI aktif, yakın kızıl ötesi bölgesi temelli 
fonksiyonel nanomalzemeler hazırlamak için çok disiplinli bir yaklaşım 
kullanılmıştır. Bu yaklaşım şunları içermektedir: (i) silica kaplı süper 
paramanyetik demir oksit nanoparçacıklarını hazırlamak için (çekirdek-kabuk), 
nanokimya, (ii) fotoduyarlaştırıcı olarak yakın kızıl ötesi bölgede absorplayan dört 
 vi
farklı bodipy çeşidini sentezlemek için, organik kimya ve (iii) singlet oksijen 
ölçümünü kanıtlamak için, spektroskopi. Dört farklı bodipy tabanlı 
fotoduyarlaştırıcı kovalent olarak MRI aktif, biyouyumlu ve toksik olmayan 
nanotaşıyıcılara bağlayarak, singlet oksijen üretme kapasiteleri 
değerlendirilmiştir. Bu çekirdek-kabuk nanoparçalarının tanı ve terapi için 
fotoduyarlaştırıcı taşımada ümit verici olduğu gösterilmiştir. 
 
 
Anahtar Kelimeler: Bodipy, fotodinamik terapi, fotoduyarlaştırıcı, manyetik 
rezonans görüntüleme, süper paramanyetik demir oksit nanoparçacık, çekirdek-
kabuk nanoparçacık 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Photodynamic Therapy 
 
For more than 25 years, photodynamic therapy (PDT) has been recognized as a 
non-invasive therapeutic procedure in malignant cancer treatment, it is now 
starting to be implemented clinically.1 Compared to existing treatments including 
chemotherapy, radiation therapy and surgery, PDT is an efficient and selective 
technique of destroying only diseased tissues without harming healthy tissues.2 In 
addition to oncological applications, PDT is a promising tool for a diversity of 
cardiovascular, dermatogical, and ophthalmic diseases.3 In PDT, a photosensitizer 
(PS) which is defined as non-toxic drug or dye is administered systemically, 
locally, or topically.4, 5 After an incubation period, it accumulates in the malignant 
tissue selectively (Fig. 1). Then, a tumor locus is illuminated with a light of 
appropriate wavelength which results in activation of PSs. In the presence of 
oxygen, these activated PSs lead to the generation of cytotoxic species and highly 
toxic singlet oxygen (1O2) and finally to cell death and tissue damage.6, 7 
 
 
Figure 1: The Principles of Photodynamic Therapy (PDT).8 Copyright © 2011 
American Cancer Society. Adapted with permission. 
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1.2 Elements that Play a Significant Role in Photodynamic 
Therapy 
 
Three main elements are required to produce singlet oxygen for PDT, namely; a 
photosensitizer, appropriate wavelength of light, and oxygen.9 If one of these 
components lacks, the technique cannot be succeeded to treat malignant tumors. 
In addition, understanding photochemistry & photophysics of PDT and 
subcellular localization of PSs is essential in order to make rational selection from 
various types of PSs and light sources available and design novel 
photosensitizers.10 
 
 
1.2.1 Photophysics and Photochemistry of PDT 
 
Fig. 2 graphically demonstrates the mechanism of light absorption and energy 
transfer that are at the core of PDT. The ground state PS possesses two electrons 
with opposite spins located in the low energy molecular orbital. Since two 
electrons have opposite spins in a molecular orbital, this is known as singlet state. 
When PS at singlet ground state is irradiated with light, the absorption of light 
(photons) gives rise to a removal of one electron to a higher energy orbital with 
keeping its spin (first excited singlet state). The resulting excited PS is short lived 
(nanoseconds) species, and due to its instability it can lose its energy by 
fluorescence (by emitting light) or heat. Instead, excited PS may consume its 
excess energy by intersystem crossing in order to create more stable (long-lived 
(microseconds)) excited triplet state specie that has electrons which spin in a 
parallel conformation.10,11 
  
The PS in triplet excited state can loss its energy by various ways (Fig. 2). One of 
them is spin forbidden transfer of electron at excited triplet state to singlet state 
directly. This is known as emission of light (phosphorescence).9 
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 In addition to phosphorescence process, the PS excited triplet can undergo two 
kinds of reactions to form cytotoxic species: Type I and Type II processes.10 Both 
Type I and Type II processes can take place at the same time, and the ratio   
between these reactions depend on the sort of PS used, as well as the 
concentrations of substrate which takes place in type I reaction and oxygen.12,13  
 
 
Figure 2: Schematic representation of the photophysical and photochemical 
mechanisms of PDT  
 
In Type I reaction, PS at triplet excited state reacts directly with a substrate such 
as an organic molecule in a cellular microenvironment or cell membrane and 
transport a proton or an electron to create a radical anion or cation, respectively. 
Reactive oxygen species (ROS) may be formed as a result of further reactions 
between these radicals and oxygen.12 
 
Firstly, a superoxide anion radical (O2· -) is formed due to electron transfer from 
the triplet PS to molecular oxygen.14,15 Superoxide itself is not biologically 
reactive and does not lead to oxidative damage. It can undergo reaction with itself 
(known as dismutation reaction) to create hydrogen peroxide (H2O2) and oxygen 
which is catalyzed by superoxide dismutase (SOD) enzyme. Hydrogen peroxide 
which have biological importance in terms of maintainability of enzyme 
functionality in cells undergo one-electron reduction to form a strong and literally 
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indiscriminate oxidant hydroxyl radical (HO•). In the process of hydroxy radical 
formation, superoxide donates one electron to reduce metal ions in cell medium. 
Then, these reduced metal ions catalyze the cleavage of the oxygen-oxygen bond 
of hydrogen peroxide to generate a hydroxyl radical (HO•) and a hydroxide ion 
(HO-). In addition, singlet oxygen can be generated due to the reaction between 
the hydroxyl radical (HO•) and superoxide.16,17  
 
This powerful oxidizing agent (HO•) radical can easily react with any organic 
molecule in cellular environment. The resulting substrates are again a radical, and 
can react with other molecules in chain reactions. Generation of these ROS due to 
chain reactions is responsible for the damage to various cell membranes including 
mitochondria, lysosomal and nuclear membranes.10,12  
 
In Type II reaction, PS at excited triplet state transfer its energy to molecular 
oxygen (3O2) in order to form excited state singlet oxygen (1O2) which shows high 
cytotoxicity. Formation of ROS via Type II process is mechanistically easier than 
via Type I process. Therefore, most PSs are considered to operate via Type II 
process.16,8 
 
1.2.2 Photosensitizers 
 
One of the most critical factors in PDT is the photosensitizer, which must be 
positioned at the site of tumor loci, absorb suitable wavelength of light and 
generate biological response.18 A great number of photosensitizers have been 
tested in vitro and in vivo in PDT experiments, but very small number of them has 
shown ideal properties. As a result, latest studies have focused on the 
improvement and efficiency of novel photosensitizers.  
 
The ideal photosensitizer should meet some necessities18,19 (1) be chemically pure 
with invariable composition and a steady shelf life, (2) be ideally water soluble or 
soluble in a risk-free aqueous solvent mixture, (3) not aggregate improperly in 
biological environments which decrease photochemical efficacy, (4) have low 
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level of dark toxicity and low occurrence of administrative toxicity (i.e. allergic 
reactions or hypotension), (5) absorb light with high absorption coefficients 
(>20,000-30,000M−1 cm−1) in order to reduce the dose of PSs needed to attain the 
desired effect, (6) absorb light in the red or far-red wavelengths (600-800 nm), (7) 
be easily and cheaply synthesized and modified to make large scale production 
possible, (8) have short time period between injection and maximum 
accumulation at tumor loci and should be eliminated from the patient rapidly in 
order to avoid side effects of light exposure, (9) have a high quantum yield for 
singlet oxygen or super oxide generation.20 The reason why absorption 
wavelength of photosensitizers is needed to be between 600 – 800 nm is that at 
shorter wavelengths, tissue penetration of light is very small and skin 
photosensitivity is high ( the power in sunlight is elevated at ʎ < 600 nm). In 
addition, at high wavelengths (> 800 nm) the photons have not sufficient energy 
to produce singlet oxygen since energy at PS triplet state cannot be transferred to 
the gound state oxygen molecule to stimulate it to the singlet state21. Through the 
use of optical fibers of appropriate wavelength, PSs at tumor sites can be 
illuminated externally or internally (endoscopically).18 
 
In addition, photosensitizers possessing heavy atoms (i.e. bromine, iodine) in their 
structures were proved to generate singlet oxygen more effectively when 
compared to the ones without heavy atoms. O’Shea et al. studied this phenomenon 
in BODIPY dyes and observed that presence of two bromine atom in molecule 
increases the effectiveness of singlet oxygen generation up to thousand folds. This 
observation is a result of increase in intersystem crossing due to heavy atom 
effect.22 ISC is spin-forbidden process since electrons transfer from a singlet to a 
triplet excited state within a molecule and this process happens ineffectively for 
many compounds. Increase in spin-orbit coupling is required to make transition 
between states of different spin multiplicities much easier. 
 
Spin-orbit Hamiltonian term is relative to fourth power of Z. Thus, existence of 
heavy atom enhances spin-orbit perturbation and spin forbidden singlet-triplet 
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radiationless transition (ISC). Spin- orbit Hamiltonian formulation for hydrogen- 
like atom is shown below.23,,24 
                                                                   
                                                                                                                                                       
                                                                                                                    (1) 
 
 
Where ao is Bohr’s radius, m is mass of electron, c is speed of light, n is principle 
quantum number, e is electron charge, Z is atomic number, L is angular 
momentum operator and S is spin operator. 
 
 
1.2.3 Light Delivery & Light Sources 
 
In order to achieve effective PDT action in vivo, adequate light should reach all 
the diseased tissue. In PDT, predicting spatial/temporal distribution of light 
through the tissue is prominent. When light enters the tissue, it is either absorbed 
or scattered and the degree of both routes depends on the wavelength of light and 
tissue type. Scattering is the most significant element restricting light 
penetration.10  
 
Scattering is mainly due to turbidity of tissue since there are lots of 
inhomogenities such as cell organelles, macromolecules, organized cell structures 
etc. This turbid environment led to multiple scattering of light which in turn cause 
spreading of a light beam and loss of directionality. Absorption is mainly because 
of important tissue chromophores such as myoglobin, hemoglobin and 
cytochromes.11 These factors are minimal between 600 and 1200 nm which is 
called ‘optical window of tissue’. Therefore, red and infrared light penetrate more 
deeply through tissue, whereas blue light penetrates less effectively (Fig. 3). On 
the other hand, light up to approximately 800 nm can produce singlet oxygen 
(1O2) since energy of longer wavelengths is not enough to trigger photodynamic 
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action. For PDT action, the typical efficient penetration depth is about 1—3 mm 
at near approximately 600 nm (intensity is reduced by 37 %), while penetration is 
approximately twice that at 700-850 nm. Thus, synthesis of novel PSs absorbing 
at longer wavelengths is prominent.25,26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Light penetration through the tissues.8 Copyright © 2011 American 
Cancer Society. Adapted with permission. 
 
 
PS should be illuminated such a light source that it should display appropriate 
spectral characteristics that overlap with the maximum absorption wavelength 
range of the PS. In addition, light source should be selected with respect to disease 
characteristic (size of lesions, accessibility, and location) and cost.17,27  
 
Light-emitting diodes (LEDs), lasers, and incandescent light sources have been 
implemented for PDT. Incandescent light sources and lasers display comparable 
efficiencies. However, lasers offer the precise selection of wavelengths and the 
specific application of light when compared to conventional incandescent lamps. 
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Among type of lasers, semiconductor diode lasers are generally preferred due to 
minimal cost, easier installation, calibration features and extended operational life. 
In addition, the introduction of lasers attached into fibers reformed PDT by 
allowing the endoscopic delivery of light to nearly every locus deep in the body 
under image guidance.28,29,30 
 
 
1.2.4 Pathways of PDT Triggered Cell Damage  
 
Within few minutes after irradiation, plasma membrane damage can be detected 
as result of PDT action. Since sensitizers do not have tendency to cover in cell 
nuclei, DNA damage, carcinogenesis, and mutations are rarely expected 
pathways31. The plasma membrane damage can be noticed as flaking of vesicles 
containing lysosomal and cytosolic enyzmes, swelling, blebbing, plasma 
membrane depolarization, active transport decrease, retardation of plasma 
membrane enzyme (Na+ K+ – ATPase) activity, regulation of surface antigens, a 
increase in Ca2+, etc.32 
 
Three different mechanisms have been accepted for contribution of tumor 
destruction due to PDT action (Fig. 4).33 Firstly, cytotoxicity due to ROS can 
cause the death of tumor cells directly by apoptosis and/or necrosis.6,11,34 
Secondly, PDT is believed to eradicate diseased tissue by the shutdown of tissue 
vasculature which leads to lack of nutrients and oxygen at the tumor loci.35 
Thirdly, discharge of stress response proteins & cytokines and inflammation 
induced by PDT in tumor loci can cause invasion of leukocytes.36,37 This 
phenomenon can both cause tumor destruction and the immune system 
stimulation which in turn lead to recognition and destruction tumor cells even at 
remote locations. These three mechanisms can affect each other. It is still unclear 
that which of these three mechanisms have significant effect on overall tumor 
damage, therefore; further research is needed.33 
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In apoptosis, cells are usually fragments into membrane enclosed vesicles called 
apoptotic bodies. These apoptotic bodies are then phagocytized by the 
neighboring cells without involving inflammation and cells die in an 
immunologically programmed way. During later stages of apoptosis, structural 
integrity of organelles and plasma membrane are still preserved. Functionality of 
the mitochondria and lysosomes are also active for quite a long period. 
Transcriptional activation of specific genes counting the activation of 
endonucleases, DNA degradation into oligonucleosomal fragments, and 
consequently activation of caspases is the significant events of apoptosis.35,38  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Pathways of PDT triggered cell damage. ROS lead apoptotic and 
necrotic cell death. Damage to microvasculature (not shown) is another reason of 
tumor destruction. PDT also triggers immune response noticed by inflammatory 
cells, such as lymphocytes, plasma cells, and macrophages.8 Copyright © 2011 
American Cancer Society. Adapted with permission.  
 
 
 
Necrosis is unprogrammed cell death pathway due to physical or chemical 
damage and considered as an accidental cell death. Unlike apoptosis, in the early 
stages of necrosis, cells begin to swell and it is followed by distruption of 
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organelles and plasma membrane followed by release of the cytoplasmic content. 
In constrast to apoptosis, necrosis induces inflammatory response in the tissue.39 
 
 
1.2.5  Localization of Photosensitizers in Subcellular Level 
 
For efficient PDT action, uptake of photosensitizers by tumor cells is crucial 
because ROS are short lived species and affect specifically the site of generation. 
Once PS enters into cells, it can localize within many cellular organelles such as 
mitochondria, lysosomes, plasma membrane, and endoplasmic reticulum.36 
Efficiency of accumulation at tumor loci and specificity of localization are mainly 
based on three factors. One of them is hydrophilic or lipophilic character of PS 
which is articulated as the logarithm of the octanol/water partition coefficient. 
Since PSs especially accumulate in the lipophilic organells of tumor cells, it is 
observed that lipophilic PSs preferentially gather at tumor loci. In additon, since 
these PSs can enter cells by passing lipophilic cell membrane, it is important to 
design drug delivery systems such as micelles, liposomes, polymeric nano and 
micro particles etc.10 
 
Generally, hydrophilic sensitizers kill tumor cells indirectly by giving harm to 
blood vessels and disrupt the supply of nutrients and oxygen. Hydrophobic drugs 
attack hyperproliferating cells with direct interactions.31  
 
Second factor is the degree of asymmetry in the sensitizers and the third one is net 
charge which can be between -4 and +4.  Hydrophobic PSs possessing two or less 
negative charges ( ≥-2) can enter the cells and localize cellular compartments. On 
the other hand, less hydrophobic PSs having more than two negative charges (<-2) 
are too polar to pass through cell membrane. Therefore, they are taken by 
endocytosis. It should be keep in mind that other elements such as lower pH at 
tumor loci can also be related to effective accumulation and uptake of PSs. Due to 
lack of oxygen and high glycolytic activity, low pH value is generally assigned for 
tumor locus. Because albumin and other serum proteins carry drugs, it is revealed 
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that there is accumulation of PSs within the vascular loci of tumor sites and the 
interstitial space.40,41,42 
 
1.3 Photosensitizers in Literature 
 
 
The majority of PSs implemented both experimentally and clinically has a 
heterocyclic ring structure similar to that of heme in hemoglobin or chlorophyll. 
In 1980s and 1990s, lots of PSs were designed and synthesized. It is still in 
progess that new ones are introduced regularly43.  
 
According to their origin and chemical structures, PSs can be classified into three 
main broad categories: (i) PSs based on porphyrin platform (e.g., Photofrin, BPD-
MA, ALA/PpIX), (ii) PSs based on chlorophyll platform (e.g., chlorins, 
bacteriochlorins, and purpurins), and (iii) dyes (e.g., napthalocyanine, 
phtalocyanine, and BODIPY) PSs which are mainly composed of the porphyrins 
introduced in the 1970s and early 1980s are named first generation PSs (e.g., 
Photofrin). After the late 1980s, porphyrin derivatives or other PSs synthesized 
are called second generation PSs (e.g., ALA). Third generation PSs usually refer 
to the alterations such as biologic conjugates (e.g., antibody or liposome 
conjugate). Although these terms are still being used, they are not acknowledged 
unanimously.43,44 
 
                     Table 1: Photosensitizer Categories 
                     Porphyrin platform 
                           HpD (hematoporphyrin derivative) 
                           HpD-based 
                           BPD (benzoporphyrin derivative) 
                           ALA (5-aminolevulinic acid) 
                           Texaphyrins 
                      Chlorophyll platform 
                           Chlorins 
                           Purpurins 
                           Bacteriochlorins 
                      Dyes 
                           Phtalocyanine 
                           Napthalocyanine 
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Natural porphyrins are entirely conjugated tetrapyrroles and differ in the number 
and sort of side groups mostly carboxylic acid groups. The main disadvantages of  
Photofrin (clinically approved) and other porphyrin-based PSs are that they have 
weak absorbance in the red region of the spectrum (therapeutic window region) 
and trigger long-term skin photosensitivity (4-6 weeks).10 
 
 
Another group is based on chlorophyll platform. Chlorin core is obtained by 
reduction of one pyrrole ring on the porphyrin periphery, and when one of pyrole 
on chlorin periphery is further reduced, it gives bacteriochlorin. Both of these 
classes absorp light at longer wavelengths (ʎmax: 730-800 nm for bacteriochlorins 
and 650-670 nm for chlorins) and they are effective singlet oxygen generators. 
Bacteriochlorins are seemed to be more efficient PSs than chlorins, however; 
there are some questions about their stability upon storage. Numerous 
bacteriochlorin and chlorin derivatives are in different stage of assessment for 
PDT.10,45  
 
 
In the dye family, phthalocyanines, naphthocyanines, and their relatives are 
mostly used in clinical trials. They have absorption band 650—850 nm range and 
most of them are hydrophobic necessitating delivery systems for clinical 
implementation like liposomes. Attaching these dyes to a diversity of metals 
seems to improve efficiency. Due to existence of four phenyl groups in the 
structure, solubility and aggregation problems are raised. Therefore, PCs are 
commonly modified with sulfonic acid groups to give water solubility.10  
 
BODIPY dyes (borondipyrromethene) have also rising potency for PDT due to 
their high photostabilities and high extinction coeffients. Since multiple chemical 
modifications can be done straightforwardly on these molecules, attachment of 
moieties that would allow selective targeting, water solubility is possible. 
Moreover, chemical groups that enhance the PDT action can be easily attached to 
BODIPY dyes.46,47 Synthetic conjugated pyrrolic ring systems including such 
structures as sapphyrins,48 texaphyrins,18 and porphycenes49 are also broad class 
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of potential PSs. Hypericin comes from this class. Another broad class is 
composed of non-tetrapyrrole derived natural or synthetic dyes such as toluidine 
blue O and Rose Bengal.10 
 
 
       Rose Bengal                                      Phthalocyanine                                     Chlorin Dyes 
 
       
        Hematoporphyrin                             Hypericin                                Texaphyrin 
                            
 
 
 
 
 
 
     
 
                              Photofrin                                 BODIPY- based photosensitizer 
Figure 5: Structures of Some Photosensitizers in Literature. 
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1.4 Clinical Applications of PDT 
 
 
Numerous products can act as PS and new ones are frequently introduced. 
However, few of them have been implemented into clinical studies and even 
fewer commercially exist. Table 2 demonstrates currently available PSs.19 
 
Table 2: Photosensitizers on the Market 
Platform Drug Substance Manufacturer 
Porphyrin Photofrin® HpD Axcan Pharma, Inc. 
Porphyrin Levulan® ALA DUSA Pharma, Inc. 
Porphyrin Metvix® M-ALA PhotoCure ASA 
Porphyrin Visudyne® Vertiporfin Novartis Pharmaceuticals 
Texaphyrin Antrin® Lutexaphyrin Pharmacyclics 
Chlorin Foscan® Temoporfin Biolitec Pharma Ltd. 
Chlorin LS11 Talaporfin Light Science 
Chlorin Photochlor HPPH RPCl 
Dye Photosens® Phthalocyanine General Physics Institute 
 
 
Clinical methods have been proposed for different cancer types over the past 30 
years and there have been over 200 clinical studies now.18 These are including 
cancers of the head and neck,50 lung,51 bladder,52 gastrointestinal tract,53 
prostate,54 actinic keratosis, and nonmelanoma skin cancers.55 Most of the patients 
response positively to PDT and when compared to other treatment methods, 
reoccurrence is very low.18 
 
For noncancerous diseases such as age-related macular degeneration, psoriasis, 
atherosclerosis, PDT is successfully employed.56,57 In addition, it is also shown 
that PDT has effect against viral diseases like herpes.58 
 
1.5 Developing Strategies in PDT 
 
 
Different approaches towards PDT are currently investigated preclinically. These 
are based on different chemistry, photophysics, and photobiological mechanism.8 
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1.5.1 Nanotechnology in PDT 
 
There are several approaches in nanotechnology to improve PDT efficacy. One of 
the significant advantages of nanoparticles is that they can be loaded with high 
concentration of PSs and modified with targeting groups such as peptides and 
antibodies. Or, photochemical and photophysical properties of PSs can be separate 
from activation and delivery process since NPs take the role of these processes.59 
Here are some examples from literature. 
 
Liposomal nanoparticles can be implemented clinically in order to make 
hydrophobic PSs water soluble.60 Biodegradable polymers, silica and metallic 
(gold, iron oxide) nanoparticles are commonly studied. Moreover, magnetic 
nanoparticles are also very useful since accumulation of NP based PSs at tumor 
loci can be enhanced by changing magnetic field.61 By designing hybrid 
nanoparticles other therapeutic strategies like hyperthermia or imaging technique 
like MRI can be coupled together. Nanotechnology provides novel approaches to 
solve problem of need for red region absorbed PSs. When quantum dots are 
attached to a PSs, they absorp the light effectively and transfer this energy to PS. 
Upconverting particles are also one of the hot topics since they can absorp at red 
region of spectrum and transformed into shorter wavelength light that illuminates 
the linked PS61. Finally, one of the latest methods is the encapsulation of PS by 
polymeric NPs. Then, it is integrated into liposomes possessing a second 
antiangiogenic agent.62 
 
 
1.5.2 PDT Molecular Beacons 
 
 
PDT molecular beacons (MBs) are designed in such a way that they enable 
controlled production of singlet oxygen with a high tumor-to-nontumor 
specificity, therefore; damage to healthy tissues is minimized. In MBs, a 
quenching molecule is attached to PS, so that PS cannot generate singlet oxygen 
until the linker between quencher and PS is cleaved. In some designs, other 
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unquenching methods are used instead of cleavage. There are many approaches to 
build MB using different type of quenchers, quenching mechanisms and cleavage 
mechanisms. One of the designs is based on the usage of linkers (e.g. peptide) 
which can be easily cleaved by target specific enyzmes that are overexpressed in 
tumor cells. Singlet oxygen production capability of photosensitizer is prevented 
because of the existence of quencher in close proximity to allow Förster resonance 
energy transfer (FRET). When peptide linker is cleaved with tumor selective 
enzyme by causing removal of quencher, FRET is blocked and PDT action 
become activated (Fig. 6). Instead, oligonucleotide (hairpin) loop which is 
unfastened by hybridization to complementary mRNA can be utilized as a linker. 
When hairpin loop is opened, FRET will be prevented since quencher and PSs 
cannot become in close proximity.63,64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Photodynamic Therapy Molecular Beacons Based on Peptide Linker.8 
Copyright © 2011 American Cancer Society. Adapted with permission. 
 
There are also other approaches to activate photosensitizers. One remarkable 
model of such PSs as BODIPY derivative was synthesized by Akkaya et al (Fig. 
7). 65 In this design, photosensitizer activation requires to use two different control 
parameters functioning as a logic controller. These parameters are two important 
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physiological parameters for tumor cells; sodium and pH. In cancer cells, sodium 
concentration is higher and pH is lower when compared to healthy cells. Pyridine 
groups become protonated in acidic media and results a bathochromic shift in the 
absorbance spectrum and shifts to 660 nm. When PS is illuminated with 660 nm 
light, protonated molecules excited and show PDT action since photo-induced 
electron transfer (PET) is deactivated by Na+ binding to crown ether moiety. 
Thus, this PS was proved to have 6 times higher singlet oxygen generation 
capacity at low pH and high sodium concentration when compared to the 
condition at higher pH and lower sodium concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Logic gate based activatable photosensitizer.65 Copyright © 2009 
American Chemical Society. Adapted with permission. 
 
 
1.5.3 Two-Photon PDT 
 
 
The concept of 2-photon PDT depends on simultaneous absorption of two light 
photons upon irradiation with short (roughly 100 femtosecond) laser pulses 
having high peak power. After illumination, the succeeding photobiological and 
photochemical mechanisms are similar to that of one-photon PDT. The main 
advantage of two-photon PDT is that since each photon supplies only one-half of 
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the excitation energy, longer wavelength (near-IR) light can be implemented. It is 
reported by Starkey et al that 2-cm depth is attained for effective treatment in 
tumor xenogafts. When the penetration depth compared to that of one-photon 
absorption, this depth is noticeably geater.66,67 
 
 
1.5.4 Metronomic PDT 
 
 
Both light and PS are used at very small dose rates over an extended time (hours–
days) in metronomic PDT (mPDT). By mPDT, tumor cell-specific apoptosis is 
encouraged with nominal tissue necrosis. Up to now, primary motivation of 
mPDT is to reduce direct PDT damage to neighboring normal brain in glioma 
disease. In addition, it prevents from the damage caused by inflammatory reaction 
to PDT-triggered tumor necrosis.8 
 
 
1.6 Future of Photodynamic Therapy in Oncology 
 
Although PDT has been used in oncology more than 25 years, PDT is still 
considered to be a fresh and promising antitumor approach. Its full potential and 
range of applications have not been revealed yet. PDT has not become a 
mainstream in oncology yet due to several reasons; hospital and clinician 
opposition to a new technique, the obscurity in the introduction of the optimal 
variables for a treatment, need for low-cost and suitable light sources, and the 
principal cost of building a PDT centre. The most important reason should be that 
application of present combinations of light sources and drugs have not 
demonstrated apparent advantages over other alternatives (e.g. radiotherapy) in 
large randomized clinical studies. This condition is most likely due to the fact that 
most drugs (PSs) have not been optimal in terms of efficacy.68 
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Up to now, most PSs have been developed chemically rather than biologically, or 
clinically. Generally, focus has been given to improve optical properties of PSs, 
however; there are many problems of early PSs need to be solved. These are low 
selectivity, prolonged skin photosensitivity, and inconveniently lengthy drug-to-
light gap. To overcome existing problems, modifications of PSs moieties through 
its physicochemical properties are needed. In addition, targeting must be 
improved by tailoring PSs with moieties such as peptide scaffolds, antibodies, or 
polymers. Therefore, improved drugs without prolonged skin photosensitivity and 
with more selectivity is needed. If such drugs can be implemented, the benefits of 
PDT in regards to patient and practitioner convenience, minimal invasion in the 
body, and health economics will guarantee a considerable future role for PDT in 
oncology. Moreover, since PDT has an interdisciplinary uniqueness, it inspires 
most specialists in chemistry, physics, biology, and medicine. Thus, novel 
improvements and applications can only be restricted by their enormous 
imagination.7,8 
 
1.7 Biological Applications of Nanoparticles 
 
 
Combination of biology and material science give rise to the utilization of 
nanomaterials in biotechnology. Nanoparticles (10-100 nm) are colloidal particles 
generally synthesized in either organic or aqueous phases.69,70 Nanoparticles can 
straightforwardly flow through blood vessels and enter the target tumor cells.71  
Nanoparticles being a functional platform have great potency for broad range of 
therapeutic applications since there are various core materials existing with    
tunable surface properties.72 Uniqueness of nanoparticles in terms of utility and 
properties come from many attributes. First, similar size of nanoparticles with 
macromolecules such as proteins and polynucleic acids provides an interaction of 
nanoparticles with these molecules, therefore; allows the application of 
biosensing. In addition, the size (<100 nm) of these particles enables conjugation 
with various molecular markers, which can interact at molecular and cellular 
levels. Thus, nanoparticles can be designed straightforwardly for targeting many 
diseases.73 Moreover, nanoparticles can be tailored with a broad range of 
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semiconductor and metal core materials 
possessing functional properties like magnetic 
behavior and fluorescence.74 Moreover, the 
surface of these core materials can be modified 
with a variety of ligands with respect to purpose 
of their applications. Table 3 shows the 
characteristics of some recognized core 
materials and related probable ligands utilized 
for surface modification with their applications.  
 
Figure 8: Main Applications of Nanoparticles.75 Copyright © 2008 WILEY-VCH Verlag GmbH & 
Co. KGaA, Weinheim. Adapted with permission. 
    
There are three main area of nanoparticle application in biology (Fig. 8), namely; 
biosensing, bioimaging, drug and gene delivery.75 
      
Table 3: Characteristics, ligands, and main applications for well-known core materials 
 
Core material             Characteristics               Ligand(s)             Applications 
 
Au                    Optical absorption, fluorescence and               Thiol, disulfide,            Biomolecular recognition, 
               fluorescence quenching, stability                       phosphine, amine       delivery, sensing 
 
Ag                      Surface-enhanced fluorescence                       Thiol                            Sensing 
 
Pt                     Catalytic property                                             Thiol, phosphine,          Bio-catalyst, sensing 
                                                      amine, isocyanide 
 
CdSe                Luminescence, photo-stability                         Thiol, phosphine,         Imaging, sensing    
                                                                                                     pyridine         
 
Fe2O3                      Magnetic property                                         Dopamine derivative   MR imaging  
                                                                                                     Amine, Diol,                   biomolecule purification 
 
SiO2                Biocompatibility                                            Alkoxysilane                  Biocompatible  
                                                                                                                                           by surface coating 
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1.8  Theranostic Nanoparticles  
 
 
Theranostic nanoparticles combine diagnostic and therapeutic abilities in one 
dose.76 Nanotheranostic platforms have several advantages when compared to 
conventional delivery systems.77 One of the most important benefits of these 
nanoplatforms is the capability of targeting to diseased loci, therefore; reduce 
systemic toxicity. In addition, labile or hydrophobic drugs can be solubilized by 
including them in the medium of the nanoparticle during the formulation, which 
in turn leads to enhanced pharmacokinetics. Moreover, nanotheranostic platforms 
have geat potency to treat, image and predict therapeutic response.77  
 
One of the unique properties of theranostic nanoplatforms based systems is 
multifunctionality. These nanoparticles can be designed such a way that can hold 
various components (Fig. 9). These consist of (i) therapeutic agents, (ii) imaging 
agents, (iii) targeting agents such as peptides, antibodies, aptamers, lectins, 
proteins, and protein fragments,78 (iv) hiding agents that circumvent intrusion with 
the immune system.79-87  
                                                                         
 
 
 
 
 
 
 
 
 
 
Figure 9: Representative Theranostic Nanoparticle. Ligands on the surface of 
multifunctional nanoparticles target to specific surface receptor of tumor cells. 
Blue and yellow spheres within a core represent imaging and therapeutic agent, 
respectively.77 Copyright © 2010, American Chemical Society. Adapted with 
permission. 
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In fact, targeting to tumor loci can also be achieved without                      
attachment of targeting ligands. Accumulation at tumor loci can occur through 
passive targeting besides active targeting.  Passive targeting based on enhanced 
retention and permeation effect in tumor loci in which nanoparticles escape from 
leaky vasculature of tumor and gather nonspecifically in the diseased loci. Shape, 
size, and charge of NPs determine the effectiveness of passive targeting. NPs 
which have the following properties removed from circulation by the liver fast 
(<15 min) before gathering at lesion: (1) having zeta potential between -20 mV 
and +20 mV, (2) being larger than 100 nm, (3) possessing solid cores.88 
 
Theranostic nanoparticles provide effective method for detection of tumor 
(imaging), treatment and follow-up screening of tumor response (Fig.10).89 
Chemotherapy, nucleic acid and gene delivery, hyperthermia (photothermal 
ablation), radiation and photodynamic therapy are therapeutic strategies that can 
be coupled with one or more imaging modes for both in vivo and in vitro studies.  
 
 
Figure 10: Theranostic Nanoparticles can be decorated with various diagnostic 
and therapeutic modalities. MRI (magnetic resonance imaging), PET (positron 
emission tomography), SPECT (single photon emission computed tomography). 
 
 
Imaging probes, such as fluorescent labeling agents (e.g. organic fluorescent dyes,  
quantum dots), MRI contrast agents, and nuclear imaging agents (SPECT/ PET 
agents) can be incorporated onto either or therapeutic delivery vehicles or 
therapeutic agents.76 Imaging techniques depend on fluorescent labeling agents 
can provide monitoring at a cellular level with high-resolution images defining 
organelles inside the cell. Other techniques such as MRI, PET or SPECT are 
Theranostic Diagnostic Therapeutic = + 
MRI PET/SPECT 
            NIR Fluorescence 
Photodynamic Chemotherapy 
Radiation  Hyperthermia   Gene Therapy 
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generally preferred for in vivo studies, since they are lack of the problems of 
photobleaching and background fluorescence.76 
 
 
1.9 Magnetic Nanoparticles as Magnetic Resonance        
Imaging (MRI) Probes 
 
Metals such as iron, cobalt, and nickel or metal oxides are magnetic materials 
which can be found in wide range of devices such as hard disks, motors, 
generators, sensors, videotapes etc. Thus, there is an increasing interest to 
minimize these magnetic materials. However, very miniature scale magnetic 
materials typically 10-20 nm range display different properties from the bulk 
material. One of the most important differences is that magnetic nanoparticles 
which are smaller than single domain limit (10-20 nm) shows 
superparamagnetism at room temperature. In other words, above its Curie 
temperature, ferrimagnetic or ferromagnetic materials typically experience a 
transition to a paramagnetic state. However, when the size of MNPs becomes 
smaller in nm scale, NPs undergo unusual transition to superparamagnetism 
below Curie temperature. Superparamagnetism depends on the size of the 
MNP.90,91,92 
 
The route of magnetism depends on the spin motions and the orbitals of electrons. 
Spin and angular momentum of electrons are related with a magnetic moment.92 
Magnetic order is caused by the the interaction among the magnetic moments of 
atoms in the below a certain temperature.93 Magnetic domains are region of bulk 
magnetic materials in which there is an alignment of magnetic moments. When 
the size of material is minimized, every MNPs become one single domain and 
magnetic properties are changed.94 
 
 
Since every MNPs are single domain, thermal energy is enough to alter 
magnetization spontaneously within each MNP and this cause 
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superparamagnetism phenomena. The reason of this phenomena is free random 
rotation of magnetic moments of each particle (in correlation with orientation of 
MNPs) under the influence of temperature (Fig.11). Therefore, the net magnetic 
moment of the MNPs is zero at sufficient temperature in the nonexistence of an 
electromagnetic field. On the other hand, there will be a net statistical 
arrangement of magnetic moments in the existence of a field causing large 
constant magnetic moment. This concept is analogous to that of paramagnetic 
materials, but this case all MNPs behave like a huge paramagnetic atom. MNPs 
containing many atoms respond fast to applied magnetic field with negligible 
residual magnetism and coercivity. Coercivity is the field necessary to convey to 
magnetization to zero. Since the probability of agglomeration is small at room 
temperature, superparamagnetic nanoparticles can be implemented for various 
biomedical applications.90,94 Susceptibility (w) and coercivity (Hc) of MNPs 
which are main factors effecting magnetic properties is determined by the shape 
and size of MNPs, crystallogaphic structure, vacancies & defects, composition, 
and magnetic anisotropy.95 
 
 
Figure 11: Aligment of Magnetic Moments of MNPs in the Absence and in the 
Presence of Magnetic Field. 
 
Upon storage on longer periods, it is usual that MNPs tend to aggregate since they 
want to minimize energy related to the high surface area. In addition, bare 
nanoparticles are chemically instable because they can simply oxidized in air 
which leads to loss of dispersibility and magnetism. To prevent these kinds of 
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situations, coating of MNPs plays a critical role. Coatings can be done with 
inorganic layer such as carbon, silica; organic layer such as polymers or 
surfactants. In addition, by the usage of these layers further modifications like 
attachment of various ligands or other nanoparticles is possible.90 However, 
coating of MNPs can lead to decrease in the saturation magnetization.96 
 
 
1.9.1 Basic Principles of MRI Contrast Improvement 
 
 When magnetic field is applied, magnetic dipole moment of MNPs is induced 
causing to creation of local magnetic fields. This causes the decrease of relaxation 
times (T1 and T2) of water molecules which diffuse into the edge of induced 
dipole moment. This is called proton relaxation and enhancement effect and cause 
the adjustment of the Nuclear Magnetic Resonance (NMR) signal intensity which 
results in the darkening in T2- weighted MRI images (Fig. 12).97,98   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Proton Relaxation and Enhancement Effect of MNPs in MRI.97 
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Adapted 
with permission. 
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Spin–spin relaxivity R2 (R2=1/T2) represents the level of T2 contrast effect. 
Higher the value of R2 leads to greater contrast impact. T1 and T2 represent the 
longitudinal and transverse proton relaxation times, respectively. T1 is related to 
reorganization of the nuclear spin population to attain the thermal equilibrium 
distribution. T1 evaluates dipolar coupling of the proton moments to neighboring. 
T2 is associated to the ‘decoherence’ of magnetization of the protons that have 
magnetic interactions with each other and with other inconsistent moments in 
neighboring.98,99 
 
 
1.9.2 Superparamagnetic Iron Oxide Nanoparticles       
 
Generally, larger magnetic moments are preferred for most application since it 
minimizes the amount of MNPs necessary. On the other hand, biocompatibility 
has great importance for biological applications. Thus, a balance between 
necessity of biocompatibility and larger magnetic moments should be reached. 
Therefore, iron oxide superparamagnetic particles (SPIONs) are often preferred to 
other superparamagnetic metals which are more toxic.98,100 Up to now, SPIONs 
have been used in humans for MRI diagnosis. However, in a near future they are 
expected to be utilized for therapeutic applications.101 
 
Magnetite (Fe3O4), maghemite (γ-Fe2O3), and haematite (α-Fe2O3) are types of 
SPIONs. Magnetite is promising in terms of biocompatibility among them.102  
 
SPIONs need to possess several properties in order to guarantee the effectiveness 
as MRI contrast agent. The method chosen to synthesize SPIONs affects all 
properties of SPIONs.103 SPIONs should be uniform in size since it has impact on 
the biodistribution and biocompatibility in vivo. NPs greater than 50nm in 
diameter are removed by reticulo-endothelial system (RES).104,105 Low toxicity 
and high colloidal stability of SPIONs are important since they bring SPIONs at 
the stage of clinical applications.103 They also can be attached to a range of 
enzymes, drugs, proteins, antibodies etc. for biomedical uses. Saturation 
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magnetization (electromagnetic unit/gram, [emu/g]) values are a measure of the 
magnetic moment, therefore; stronger MRI signals are obtained at higher values 
of saturation magnetization.103,104,105 Magnetization values for SPIONS are 
typically between 30-50 emu/g.105,106 The highest magnetization value occurs 
typically in the 6-20 nm particle size range.  
 
 
1.9.2.1 Chemical Routes for the Synthesis of SPIONS 
 
 
Since SPIONs have crystalline structures, synthesis involves two processes, 
nucleation and growth. Solution should be saturated for precipitation to take place 
since any excess solute added cause the formation of nanocrystals.107 The solution 
should be supersaturated for nucleation to occur which leads to a short single 
burst of nucleation. The concentration decrease and nucleation end after the short 
burst in nucleation. Then, solutes from solution diffuse onto the nuclear surfaces 
till equilibrium concentration is attained. This stage refers to growth of 
nanoparticles.108,103 Monodisperse SPIONs can be obtained if nucleation and 
growth progress separately. This can be achieved by either the end of nucleation 
or before critical supersaturation.104 
 
There are several routes for the synthesis of SPIONs for applications to MRI.104 
Method of chemical precipitation, high temperature reaction, and constrained 
environments reactions are significant ones.73  
 
 
The chemical precipitation method is the easiest pathway to obtain SPIONs.107 
Either maghemite or magnetite can be obtained by coprecipitation of 
stoichiometric combination of ferric and ferrous salts in an aqueous media. The 
pH should be between 8 and 14, and ratio of 2:1 for Fe2+/ Fe3+ should be attained. 
The precipitated magnetite is black and the overall reaction can be written as:104 
 
                Fe2+ + 2Fe3+ + 8OH- → Fe3O4 + 4H2O                     (2) 
 
 28
The reaction should be carried under nitrogen to prevent oxidation of magnetite to 
maghemite.104 
 
In high temperature method, iron complexes are decomposed in the presence of 
surfactants and organic solvents at high temperatures. SPIONs with high 
monodispersity and high crystallinity can be obtained. The resulting SPIONs are 
highly dispersible in organic solvents rather than aqueous medium.109 Sun and 
Zeng produce SPIONs in size of 4 nm by decomposition of iron (III) 
acetylacetonate upon heating to 265oC in phenyl ether, alcohol, oleic acid, and 
oleylamine.110 
 
In the method of constrained environments, formation of SPIONs progress inside 
the lipid-based structures with dendrimers or amphiphiles. In other words, iron 
oxide core is stabilized by these surfactants, which restrict particle nucleation and 
growth process. Liposomes, micelles, microemulsions, lipid based NPs are 
amphiphilic molecules that can be used for this purpose. These amphiphilic 
molecules gather into aggregates in an aqueous solution spontaneously which 
results various size and geometries such as spherical, cylindrical, and bilayered of 
SPIONs.111,112 
 
 
1.9.2.2 Silica Monolayer for Superparamagnetic Iron 
Oxide Nanoparticles 
 
SPIONs should be stabilized to prevent oxidation and aggregation. There are 
numerous ways of attaining stability and solubility. These methods can be coating 
with inorganic layers such as silica, carboxylates such as citrid acid, and polymers 
such as dextran and PEG.73 Here, silica monolayer will be discussed. 
 
Silica is an inert and biocompatible molecule that coats the surface of SPIONs. 
Layer of silica reduce aggregation and improve stability. Reduction in aggregation 
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results from sheltering of the magnetic dipole interaction by the silica shell. Since 
silica has negative charge on it, it makes SPIONs stable in aqueous medium.113,114 
 
There are two common methods for silica coating of SPIONs. One of them is 
called Stober method, and it depends on the hydrolysis and condensation of a sol-
gel precursor such as tetraethyl orthosilicate (TEOS). Second method is based on 
microemulsion process. Reverse micelles is utilized to confine and direct the silica 
coating. These reverse micelles are formed by non-ionic surfactants.115 
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CHAPTER 2 
 
EXPERIMENTAL PROCEDURES 
 
 
2.1 General 
 
                1H NMR and 13C NMR spectra were recorded on Bruker DPX–400 
(operating at 400 MHz for 1H NMR and 100 MHz for 13C NMR) in CDCl3 
solvent with tetramethylsilane as internal standard. All spectra were recorded at 
25 oC and coupling constants (J values) are given in Hz. Chemical shifts are given 
in parts per million (ppm). Mass spectra were recorded with Agilent Technologies 
6224 TOF LC/MS. Absorption spectra were performed by using a Varian Cary–
100 and Varian Cary 5000 UV-VIS-NIR absorption spectrophotometer. 
Fluorescence measurements were conducted on a Varian Eclipse 
spectrofluometer. Nano-ZS Zetasizer dynamic light scattering (DLS) system 
(Malvern Instruments, U.K.) was used to measure the particle size and surface 
charge of bodipy functionalized magnetic nanoparticles. TEM images were 
aquired in UNAM, Ankara, using FEI Technai G2 F30 high resolution 
transmission electron microscope and carbon gid. The dried, as-synthesized 
nanoparticles were characterized with X-ray powder diffractometry (XRD) 
(PANalytical X’Pert powder diffractometer, Netherlands) by using Cu Kα 
radiation in a range of 2θ = 20–70o. The infrared spectra of the nanoparticles were 
obtained by using a Fourier transform infrared spectrometer (FTIR) (Bruker-
VERTEX70, Germany). X-ray photoelectron spectroscopy (XPS) measurements 
were carried with Thermo Scientific, K-Alpha-Monochromated high-performance 
XPS spectrometer. VSM measurements have been performed with use of 
Quantum Design PPMS (9T) system at the Gebze Institute of Technology,  
Gebze-Kocaeli, Turkey.    
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 All chemicals and solvents purchased from Aldrich and Merck were used without 
further purification. Column chromatography of all products was performed using 
Merck Silica Gel 60 (particle size: 0.040–0.063 mm, 230–400 mesh ASTM). 
Reactions were monitored by thin layer chromatography using Merck TLC Silica 
gel 60 F254. Anhydrous tetrahydrofuran was obtained by refluxing over 
sodium/benzophenone prior to use. In singlet oxygen measurements 1,3-
Diphenylisobenzofuran was used as a singlet oxygen trap in dichloromethane and 
isopropyl alcohol measurements and was purchased from Sigma.  
 
2.2 Experimental Part 
 
2.2.1 Design of Nanoplatform for PDT and MRI 
 
 
 
 
 
 
 
 
 
 
Figure 13: Representative Design of Target Nanoplatform 
 
 In this study, four different BODIPY-based PSs (Compound 13, 14, 15, 16) are 
attached to SPIONs core- silica shell nanoparticles. Bromines are attached to 
enhance intersystem crossing, thus provide spin forbidden singlet-triplet transition 
leading to enhanced singlet oxygen production. In our design, SPIONs are 
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synthesized as a MRI contrast agent. Then, it is covered with silica shell which 
prevents agglomeration of SPIONs. In addition, it provides a platform which is 
easily functionalized. 
 
2.2.2 Synthesis of Photosensitizers 
 
2.2.2.1 Synthesis of Compounds 2, 3, 4, 5 
 
 
Figure 14: Synthesis of Compounds 2, 3, 4, 5 
 
 
Synthesis of Compound 2: 
 
 1,4-hydroxybenzaldehyde (1.25 g, 10 mmol) and 1,10 dibromodecane (9.2 mL, 
40 mmol) were dissolved in acetone (400 mL). K2CO3 (6.9 g, 50 mmol) and a few 
crystals of 18-crown–6 were added. The reaction mixture was refluxed for 24 h at 
55–56 oC. Then, acetone was evaporated in vacuo and extracted with water and 
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chloroform. Organic layer is dried with Na2SO4 and evaporated in vacuo. The 
product was purified by silica gel column chromatography using Hex/EtOAc 
(75:25, v/v). Fraction containing compound 2 was collected, then the solvent was 
removed under reduced pressure to yield the desired product as a white solid (1.69 
g, 48.3% ). 
 
1H NMR (400 MHz, CDCl3): δ 9.90 (s, 1H), 7.89 – 7.79 (m, 2H), 7.01 (dd, J = 
9.1, 2.2 Hz, 2H), 4.06 (t, J = 6.5 Hz, 2H), 3.43 (t, J = 6.9 Hz, 2H), 1.93 – 1.76 (m, 
4H), 1.48 (td, J = 14.3, 7.0 Hz, 4H), 1.43 – 1.22 (m, 9H).  
 
13C NMR (100 MHz, CDCl3, δ ppm): 190.42, 164.14, 131.83, 129.71, 114.68, 
68.31, 33.92, 32.76, 29.37, 29.30, 29.23, 29.00, 28.68, 28.10, 25.89. MS HRMS 
(TOF-APCI): m/z calculated for [M+H]+ 341. 1100, found 341.1098, ∆ = -0.58 
ppm 
 
 
Synthesis of Compound 3: 
 
 4-(10-bromodecyloxy) benzaldehyde, compound 2, (1.5 g, 4.4 mmol) and NaN3 
(2.3 g, 35.2 mmol) were dissolved in 20 mL DMF. Then, a few crystals of benzo-
18-crown-6 and 100 mg KI were added to the reaction flask. This reaction mixture 
was then heated to 80 οC and stirred at this temperature for 48 hours. The mixture 
was extracted six times with water and chloroform to remove DMF. Organic layer 
was dried with Na2SO4 and evaporated in vacuo. The product was purified by 
silica gel column chromatography using CHCl3/Hex (1:2, v/v). Fraction 
containing compound 3 was collected, then the solvent was removed under 
reduced pressure to yield the brown oily product (1.29 g, 96.9% ). 
 
1H NMR (400 MHz, CDCl3): δ 9.80 (s, 1H), 7.81 – 7.62 (m, 2H), 6.96 – 6.77 (m, 
2H), 3.96 (t, J = 6.5 Hz, 3H), 3.18 (t, J = 6.9 Hz, 3H), 1.73 (dq, J = 13.1, 6.6 Hz, 
3H), 1.57 – 1.46 (m, 3H), 1.44 – 1.33 (m, 3H), 1.26 (d, J = 16.9 Hz, 13H). 
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13C NMR (100 MHz, CDCl3, δ ppm): 190.7, 164.26, 131.97, 129.77, 114.75, 
68.39, 51.47, 29.40, 29.37, 29.27, 29.09, 29.04, 28.82, 26.69, 25.93.  MS HRMS 
(TOF-APCI): m/z calculated for [M+H]+  304.2001, found 304.2005, ∆ = 1.32 
ppm 
 
Synthesis of Compound 4: 
 
  4-(10-azidodecyloxy) benzaldehyde, compound 3, (1 g, 3.30 mmol)  and 2,4-
dimethyl pyrrole (0.725 g, 7.6 mmol) were added to 400 mL CH2Cl2 which was 
purged with Ar for 30 min. The color of the solution turned into red after the 
addition of 3 drops of trifluoroacetic acid. The reaction mixture was stirred at 
room temperature for 24 h. After 24 h, 1.054 g DDQ (2,3-dichloro-5,6-
dicyanobenzoquinone) was added and the reaction mixture was stirred at room 
temperature for 60 min. Then, triethyl amine (5 mL) and boron trifluoride diethyl 
etherate (5 mL) were added sequentially. After stirring at room temperature for 60 
min, it was extracted with water. Organic layer was dried with Na2SO4 and 
evaporated under vacuo. First, the product was purified by silica gel column 
chromatography using CHCl3. Then, second silica gel column chromatography 
using Hex/EtOAc (3:1, v/v) was performed for further purification. Fraction 
containing compound 4 was collected, and then the solvent was removed under 
reduced pressure (414 mg, 0.79 mmol, 24 % ).  
 
1H NMR (400 MHz, CDCl3): δ 7.05 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 10.3 Hz, 
2H), 5.89 (s, 2H), 3.92 (t, J = 6.6 Hz, 2H), 3.14 (t, J = 6.9 Hz, 2H), 2.46 (s, 6H), 
1.79 – 1.68 (m, 2H), 1.57 – 1.46 (m, 2H), 1.40 (m, J = 14.8, 7.0 Hz, 2H), 1.35 (s, 
6H), 1.32 – 1.21 (m, 12H). 
  
13C NMR (100 MHz, CDCl3, δ ppm): 159.74, 155.18, 143.17, 142.01, 128.38, 
126.81, 121.07, 116.98, 114.04, 68.14, 51.47, 29.44, 29.40, 29.26, 29.13, 28.84, 
26.71, 26.06, 14.56. MS HRMS (TOF-APCI): m/z calculated for [M] + 521.3100, 
found 521.3131, ∆ = 5.95 ppm 
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Synthesis of Compound 5: 
 
 1,3,5,7-Tetramethyl-8-(4-(10-azidodecyloxy))-4,4-difloroboradiaza-s indacene, 
compound 4, (200 mg, 0.384 mmol) was dissolved in DMF/DCM mixture ( 15 
mL: 15 mL). Then, N-bromosuccinimide; NBS (0.157 g, 0.882 mmol) was 
dissolved in 15 mL DCM and added to previous solution dropwise. Followed by 
TLC, it was stirred at room temperature for 45 min. Then, it was extracted with 
water and dichloromethane five times. Organic layer was dried with Na2SO4 and 
evaporated in vacuo. The product was purified by silica gel column 
chromatography using Hex/EtOAc (5.25:1, v/v). Fraction containing compound 5 
was collected, then the solvent was removed under reduced pressure to give red 
waxy product (247 mg, 0.365 mmol, 95 %). 
 
1H NMR (400 MHz, CDCl3): δ 7.14 (d, 2H), 7.04 (d, J = 4.1, 2.3 Hz, 2H), 4.04 (t, 
J = 6.4 Hz, 2H), 3.28 (t, J = 6.4 Hz 2H), 2.62 (s, 6H), 1.89 – 1.79 (m, 2H), 1.63 
(p, J = 6.8 Hz, 2H), 1.51 (dd, J = 14.9, 7.6 Hz, 2H), 1.45 (s, 6H), 1.38 (d, J = 16.9 
Hz, 10H).   
 
13C NMR (100 MHz, CDCl3, δ ppm): 160.15, 153.68, 142.48, 140.66, 130.62, 
129.55, 127.44, 126.09, 116.52, 111.65, 68.19, 51.48, 29.44, 29.40, 29.22, 29.14, 
28.85, 26.72, 26.05, 23.76, 22.99, 13.86, 13.65. MS HRMS (TOF-APCI): m/z 
calculated for [M-F]+ 660.1343, found 660.1362 , ∆ = -2.88 ppm 
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2.2.2.2 Synthesis of Compounds 7 and 8 
 
 
 
Figure 15: Synthesis of Compounds 7 and 8 
 
Synthesis of Compound 7:  
 
 Compound 7, p-aminophenyl propargyl ether, was prepared according to the 
literature.115 Stannous chloride dihydrate (10.15 g, 45 mmol) was dissolved in 25 
mL concentrated HCl. Then, cooled solution of stannous chloride dihydrate was 
added dropwise to a solution of p-nitrophenyl propargyl ether (1.595 g, 9 mmol) 
in dioxane at 10 oC. The reaction mixture was stirred for 48 h at room 
temperature. Then, it was neutralized with aqueous sodium hydroxide, the 
solution was extracted with dichloromethane (4 × 50 mL). Organic layer was 
dried with Na2SO4 and evaporated in vacuo. The product was purified by silica 
gel column chromatography using CHCl3/Hex (3:1, v/v). After the removal of 
solvent under reduced pressure, it was crystallized to yield brownish platelet 
crystals (800 mg, 65 %). 
 
1H NMR (400 MHz, CDCl3): δ 6.76 – 6.72 (m, 2H), 6.72 – 6.45 (m, 2H), 4.51 (t,  
J = 2.0 Hz, 2H), 3.37 (s, 2H), 2.49 – 2.32 (m, 1H).   
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13C NMR (100 MHz, CDCl3, δ ppm): 150.70, 140.97, 116.42, 116.23, 79.16, 
75.17, 56.76 MS HRMS (TOF-APCI): m/z calculated for [M+H]+ 148.0762, 
found 148.0765 , ∆ = 0.01 ppm 
 
 
Synthesis of Compound 8:  
 
 Compound 8, p-isothiocyanatophenyl propargyl ether, was synthesized 
according to the literature with slight modifications.116 Compound 7, p-
aminophenyl propargyl ether, (600 mg, 4.08 mmol) is dissolved in acetone (5 
mL). Then, carbon disulfide (0.2 mL), triethylamine (2.3 mL) was added to the 
reaction mixture.  
 
 The mixture was allowed to stir at room temperature for 1 h. Catalytic amount 
ferrous sulfate and triethylamine was added to this reaction flask, and the stirring 
was continued for 2 h. When starting material was consumed, excess carbon 
disulfide was removed by distillation. After quenching the reaction mass in 25 mL 
ice-cold water with constant stirring, the product was isolated by filtration and 
dried under vacuo. The product was purified by silica gel column chromatography 
using CHCl3/Hex (50:50, v/v). Fraction containing compound 8 was collected, 
then the solvent was removed under reduced pressure to yield the white platelet 
crystals (341 mg, 44 %).  
 
1H NMR (400 MHz, CDCl3): δ 7.31 – 7.14 (m, 2H), 7.01 – 6.89 (m, 2H), 4.70 
(dd, J = 12.7, 2.4 Hz, 2H), 2.59 – 2.50 (m, 1H).  
 
13C NMR (100 MHz, CDCl3, δ ppm):  155.69, 134.29, 126.25, 123.87, 115.20, 
77.18, 75.37, 55.38. MS HRMS (TOF-APCI): m/z calculated for [M-NCS]- 
132.0575, found 132.0315, ∆ = 196. 88 ppm 
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2.2.2.3 Synthesis of Compound 9 
 
 
 
 
Figure 16: Synthesis of Compound 9 
 
 2,6-Dibromo-1,3,5,7-Tetramethyl-8-(4-(10-azidodecyloxy))-4,4 difloroboradiaza-
s-indacene, compound 5, (190 mg, 0.292 mmol) and 4-methoxybenzaldehyde 
(318 mg, 2.34 mmol) were dissolved in benzene (45 mL). Piperidine (0.5 mL) and 
glacial acetic acid (0.5 mL) were added respectively. The reaction mixture was 
refluxed using Dean-Stark apparatus at 110 oC. When the solution was 
concentrated, reaction was followed by TLC until dark green colored product 
became the major product. Then, benzene was evaporated in vacuo. It was 
extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and 
evaporated under reduced pressure. Then, it was dissolved in minimum amount of 
chloroform and precipitated in methanol to remove aldehyde. The product was 
purified by silica gel column chromatography using CHCl3/MeOH (99:1, v/v). 
Fraction containing compound 9 was collected, then the solvent was removed 
under reduced pressure to get compound 9 as dark green powder ( 219 mg, 65% ). 
 
1H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 16.7 Hz, 2H), 7.65 (t, J = 9.8 Hz, 6H), 
7.26 (d, J = 8.5 Hz, 2H), 7.20 (t, J = 8.9 Hz, 1H), 7.06 – 6.89 (m, 13H), 6.77 (d, J 
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= 8.7 Hz, 4H), 5.71 (d, J = 16.5 Hz, 2H), 3.90 (s, 6H), 3.82 (s, 8H), 3.30 (t, J = 6.9 
Hz, 2H), 1.85 (dd, J = 14.8, 7.6 Hz, 3H), 1.64 (dd, J = 13.6, 6.8 Hz, 2H), 1.55 (d, 
J = 16.4 Hz, 4H), 1.38 (s, 12H), 1.30 – 1.22 (m, 6H).  
 
13C NMR (100 MHz, CDCl3, δ ppm): 160.79, 160.24, 159.75 , 139.20, 134.54, 
131.49, 129.75, 129.31, 127.98 , 126.94 , 126.37, 118.34, 116.14 , 115.75, 115.34, 
114.34, 113.78, 68.22, 56.08 , 55.42, 55.24, 51.50, 29.70, 29.54, 29.48, 29.19, 
28.87, 26.75, 26.30. MS HRMS (TOF-APCI): m/z calculated for [M]+  1151.3002, 
found 1151.3065, ∆ = 5.47 ppm 
 
2.2.2.4 Synthesis of Compound 10 
 
 
 
Figure 17: Synthesis of Compound 10 
 
2,6-Dibromo-1,3,5,7-Tetramethyl-8-(4-(10-azidodecyloxy))-4,4-difloroboradiaza-
s-indacene, compound 5, (100 mg, 0.154 mmol) and 4-(Dimethylamino)-
benzaldehyde (160 mg, 1.078 mmol) were added to a 100 mL round-bottomed 
flask containing 45 mL benzene. Piperidine (0.5 mL) and glacial acetic acid (0.5 
mL) were added respectively to this mixture. The reaction mixture was refluxed 
using Dean-Stark apparatus at 115 oC and the reaction was monitored by TLC. 
When black colored product became the major product, the mixture was cooled to 
room temperature and solvent was evaporated. It was extracted with CHCl3 and 
water. Organic layer was dried with Na2SO4 and evaporated under reduced 
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pressure. Then, it was dissolved in minimum amount of chloroform and 
precipitated in methanol to remove aldehyde. The product was purified by silica 
gel column chromatography using CHCl3. It yielded compound 10 as black 
colored powder (50 mg, 30%). 
 
1H NMR (400 MHz, CDCl3): δ 8.14 (d, J = 15.9 Hz, 2H), 7.60 (s, 6H), 7.21 (d, J 
= 7.1 Hz, 2H), 7.02 (d, J = 14.5 Hz, 3H), 6.89 (d, J = 7.2 Hz, 2H), 6.75 (s, 4H), 
6.57 (d, J = 7.6 Hz, 2H), 5.59 (d, J = 16.9 Hz, 1H), 3.94 (s, 2H), 3.21 (d, J = 57.3 
Hz, 2H), 3.06 (s, 12H), 2.98 (s, 6H), 1.85 (s, 3H), 1.63 (s, 3H), 1.50 (s, 6H), 1.35 
(s, 12H), 1.27 (s, 3H).   
 
13C NMR (100 MHz, CDCl3, δ ppm): 159.94, 151.21, 151.14, 150.29, 139.99, 
139.27, 134.84, 130.80, 129.39, 129.27, 127.90, 127.14, 127.01, 125.53, 125.45, 
122.56, 116.25, 115.75, 115.23, 112.1, 112.13, 111.90, 68.1 , 62.34 , 50.50, 40.35 
, 40.31, 40.28, 30.27, 29.69, 29.49, 29.45, 29.36 , 28.99, 26.49 , 26.19 , 14.11, 
8.68 . MS HRMS (TOF-APCI): m/z calculated for [M+H]+ 1073.3610, found 
1073.3669 , ∆ = 5.49 ppm 
 
2.2.2.5 Synthesis of Compound 11 
 
 
 
Figure 18: Synthesis of Compound 11 
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2,6-Dibromo-1,3,5,7-Tetramethyl-8-(4-(10-azidodecyloxy))-4,4-difloroboradiaza-
s-indacene, compound 5, (100 mg, 0.154 mmol) and trans-4-(Dimethylamino)-
cinnamaldehyde (81 mg, 0.462 mmol) were dissolved in benzene (60 mL). 
Piperidine (0.4 mL) and glacial acetic acid (0.4 mL) were added respectively. The 
reaction mixture was refluxed using Dean-Stark apparatus at 100 oC. When the 
solution was concentrated, reaction was followed by TLC until black colored 
product became the major product. Then, benzene was evaporated in vacuo. It 
was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and 
evaporated under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3/Hex (75:25, v/v). Fraction containing compound 11 
was collected then the solvent was removed under reduced pressure (70 mg, 
46%). 
 
1H NMR (400 MHz, CDCl3): δ 8.15 (dd, J = 16.4, 11.0 Hz, 1H), 8.09 – 7.96 (m, 
1H), 7.67 – 7.56 (m, 3H), 7.42 (dd, J = 11.7, 9.5 Hz, 2H), 7.26 – 7.13 (m, 3H), 
7.06 – 6.95 (m, 3H), 6.84 (dd, J = 15.2, 8.8 Hz, 1H), 6.73 (dt, J = 22.1, 9.9 Hz, 
4H), 4.05 (t, J = 6.3 Hz, 2H), 3.28 (t, 2H), 3.07 (s, 6H), 3.04 (s, 5H), 1.86 (s, 2H), 
1.63 (dd, J = 13.6, 6.7 Hz, 2H), 1.52 (dd, J = 17.3, 9.9 Hz, 3H), 1.50 – 1.44 (m, 
6H), 1.36 (s, 11H).  
 
13C NMR (100 MHz, CDCl3, δ ppm): 159.93, 151.22, 150.56, 140.0,139.56, 
139.17, 138.39, 137.93, 129.86, 129.43, 129.34, 128.55, 128.48, 127.06, 126.44, 
126.32, 125.45, 125.34, 119.90, 115.16, 113.91, 112.17, 68.22 , 51.50, 40.29, 
29.45, 29.41, 29.25, 29.15, 28.85, 26.73, 26.06, 13.89 , 13.86, 13.76. MS HRMS 
(TOF-APCI): m/z calculated for [M]+ 993.3110, found 993.3131, ∆ = 2.11 ppm 
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2.2.2.6 Synthesis of Compound 12 
 
 
 
 
Figure 19: Synthesis of Compound 12 
 
 
2,6-Dibromo-1,3,5,7-Tetramethyl-8-(4-(10-azidodecyloxy))-4,4-difloroboradiaza-
s-indacene, compound 4, (100 mg, 0.154 mmol) and trans-4-
methoxycinnamaldehyde (75 mg, 0.462 mmol) were added to a 100 mL round-
bottomed flask containing 60 mL benzene. Piperidine (0.4 mL) and glacial acetic 
acid (0.4 mL) were added respectively to this mixture. The reaction mixture was 
refluxed using Dean-Stark apparatus at 95 oC and the reaction was monitored by 
TLC. When green colored product became the major product, the mixture was 
cooled to room temperature and solvent was evaporated. It was extracted with 
CHCl3 and water. Organic layer was dried with Na2SO4 and evaporated under 
reduced pressure. The product was purified by silica gel column chromatography 
using CHCl3/Hex (80:20, v/v). It yielded light green colored powder (82 mg, 
55%). 
 
1H NMR (400 MHz, CDCl3): δ 8.01 (t, J = 18.1 Hz, 1H), 7.92 (dd, J = 15.7, 10.7 
Hz, 1H), 7.60 – 7.44 (m, 2H), 7.37 (dd, J = 8.7, 3.5 Hz, 3H), 7.19 (dd, J = 15.7, 
10.7 Hz, 2H), 7.10 – 6.98 (m, 2H), 6.97 – 6.90 (m, 2H), 6.87 (dd, J = 15.2, 6.6 Hz, 
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2H), 6.85 – 6.70 (m, 4H), 3.94 (t, J = 6.5 Hz, 2H), 3.74 (dt, J = 12.5, 9.5 Hz, 6H), 
3.19 (t, J = 6.9 Hz, 2H), 1.82 – 1.63 (m, 2H), 1.59 – 1.48 (m, 2H), 1.45 – 1.35 (m, 
7H), 1.35 – 1.16 (m, 13H).  
 
13C NMR (101 MHz, CDCl3): δ 167.75, 160.76 , 160.09 , 132.47, 130.87, 129.85 
129.64, 129.27, 128.80, 128.42, 126.68, 115.30, 114.32, 68.20, 55.38, 51.49, 
38.74, 30.37, 29.70, 29.3, 28.89, 26.72, 26.05, 23.75, 22.83, 14.21, 13.59, 10.96. 
MS HRMS (TOF-APCI): m/z calculated for [M-H]-  966.2399, found 966.2211, ∆ 
= -19.46 ppm 
 
 
2.2.2.7 Synthesis of Compound 13 
 
Both compound 8 (0.13 mmol, 24 mg) and compound 9 (0.065 mmol, 75 mg) 
were dissolved in a 10 mL round-bottomed flask containing 2 mL CHCl3 and 1 
mL EtOH. Saturated solution of Sodium ascorbate and CuSO4.5H2O were 
prepared in 1 mL water, separately. Then, 0.75 mL of CuSO4 and 0.75 mL of 
Sodium ascorbate solution were added to the flask, respectively. Catalytic amount 
of copper powder is added to this reaction mixture. The reaction was allowed to 
stirred for 8 h. Copper powder was eliminated by using filtration paper. Then, it 
was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and 
evaporated under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3/methanol (98:2, v/v). Fraction containing 
compound 13 was collected, then the solvent was removed under reduced 
pressure (56 mg, 64% ). Extinction coefficient (Ɛ); 76,633 cm-1mol-1L in CHCl3. 
ʎ abs: 698 nm 
 
 44
 
 
 
Figure 20: Synthesis of Compound 13 
 
1H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 16.6 Hz, 2H), 7.65 (d, J = 7.2 Hz, 
5H), 7.59 (t, J = 11.0 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 7.18 (dd, J = 6.8, 2.1 Hz, 
2H), 7.03 (s, 1H), 7.00 – 6.95 (m, 7H), 6.93 (d, J = 8.7 Hz, 6H), 6.76 (d, J = 8.6 
Hz, 4H), 5.70 (d, J = 16.6 Hz, 2H), 5.21 (s, 2H), 4.38 (t, J = 7.2 Hz, 2H), 3.84 (d, 
14H), 1.94 (d, J = 6.6 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.56 (d, J = 36.0 Hz, 3H), 
1.47 – 1.25 (m, 13H).  
 
13C NMR (100 MHz, CDCl3, δ ppm): 160.80, 160.22, 159.73, 157.17, 149.32, 
140.19, 139.22, 138.26, 134.44, 133.05, 131.50, 130.87, 129.83, 129.66, 129.32, 
128.80, 127.98, 127.01, 126.38, 124.23, 122.53, 118.35, 116.12, 115.75, 115.34, 
114.34, 113.78, 105.93, 68.19, 62.36, 55.34, 50.49, 30.32, 29.46, 29.36, 28.97, 
26.49, 26.27, 23.76, 22.98. MS HRMS (TOF-APCI): m/z calculated for [M]+ 
1340.3250, found 1340.3359 , ∆ = 8.13 ppm 
 
 
 
 
 
 45
2.2.2.8 Synthesis of Compound 14 
 
 
 
 
Figure 21: Synthesis of Compound 14 
 
 
Both compound 8 (0.094 mmol, 17 mg) and compound 10 (0.047 mmol, 50 mg) 
were dissolved in a 10 mL round-bottomed flask containing 1.5 mL CHCl3 and 
0.5 mL EtOH. Saturated solution of Sodium ascorbate and CuSO4.5H2O were 
prepared in 1 mL water, separately. Then, 0.75 mL of CuSO4 and 0.75 mL of 
Sodium ascorbate solution were added to the flask, respectively. Catalytic amount 
of copper powder is added to the this reaction mixture. The reaction was allowed 
to stirred for 8 h. Copper powder was eliminated by using filtration paper. Then, It 
was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and 
evaporated under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3/methanol (99:1, v/v). Fraction containing 
compound 14 was collected, then the solvent was removed under reduced 
pressure (35 mg, 59% ). Extinction coefficient (Ɛ); 57,888 cm-1mol-1L in CHCl3. 
ʎ abs: 755 nm 
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1H NMR (400 MHz, CDCl3). δ 8.08 (d, J = 3.7 Hz, 1H), 8.04 (d, J = 3.8 Hz, 1H), 
7.58 – 7.45   (m, 7H), 7.10 (ddd, J = 10.1, 8.1, 6.0 Hz, 4H), 6.96 (s, 1H), 6.89 
(ddd, J = 12.4, 7.1, 3.0 Hz, 4H), 6.81 (d, J = 8.8 Hz, 2H), 6.68 (dd, J = 8.9, 4.1 
Hz, 4H), 6.48 (d, J = 8.9 Hz, 2H), 5.50 (d, J = 16.5 Hz, 1H), 5.12 (s, 2H), 4.28 (t, 
J = 7.3 Hz, 2H), 3.98 – 3.79 (m, 2H), 2.98 (s, 11H), 2.89 (s, 6H), 1.84 (dd, J = 
16.4, 9.5 Hz, 2H), 1.80 – 1.70 (m, 2H), 1.50 (s, 2H), 1.48 – 1.38 (m, 5H), 1.37 – 
1.22 (m, 13H), 1.19 (d, J = 4.8 Hz, 4H).  
 
13C NMR (101 MHz, CDCl3): δ 159.94, 156.56, 151.21, 151.14, 150.29, 139.99, 
139.27, 134.84, 130.80, 129.39, 129.27, 127.90, 127.14, 127.01, 125.53, 125.44, 
125.37 , 122.56 , 116.25, 115.75, 115.23, 113.62, 112.16, 112.13, 111.90, 68.17, 
62.34 , 50.50 , 40.31, 30.27, 29.69, 29.43, 28.99, 26.49, 26.19, 14.11, 8.68. MS 
HRMS (TOF-APCI): m/z calculated for [M]+ 1261.3781, found 1261.3803, ∆ = 
1.74 ppm 
 
 
2.2.2.9 Synthesis of Compound 15 
 
 
 
Figure 22: Synthesis of Compound 15 
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Both compound 8 (0.065 mmol, 13 mg) and compound 11 (0.050 mmol, 50 mg) 
were dissolved in a 10 mL round-bottomed flask containing 1.5 mL CHCl3 and 
0.5 mL EtOH. Saturated solution of Sodium ascorbate and CuSO4.5H2O were 
prepared in 1 mL water, separately. Then, 0.5 mL of CuSO4 and 0.5 mL of 
Sodium ascorbate solution were added to the flask, respectively. Catalytic amount 
of copper powder is added to this reaction mixture. The reaction was allowed to 
stirred for 8 h. Copper powder was eliminated by using filtration paper. Then, It 
was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and 
evaporated under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3. Fraction containing compound 15 was collected, 
then the solvent was removed under reduced pressure (42 mg, 71%). Extinction 
coefficient (Ɛ); 59,775 cm-1mol-1L in CHCl3. ʎ abs: 746 nm 
 
 
1H NMR (400 MHz, CDCl3): δ 8.21 – 7.97 (m, 2H), 7.61 (dd, J = 12.3, 8.0 Hz, 
4H), 7.43 (d, J = 7.1 Hz, 2H), 7.32 – 7.21 (m, 1H), 7.21 – 7.07 (m, 4H), 7.06 – 
6.91 (m, 5H), 6.88 – 6.61 (m, 6H), 5.20 (s, 2H), 4.36 (t, J = 7.2 Hz, 2H), 4.04 (t, J 
= 6.2 Hz, 2H), 3.05 (dd, J = 11.9, 2.4 Hz, 12H), 1.96 – 1.74 (m, 4H), 1.47 (d, J = 
5.0 Hz, 8H), 1.28 (dd, J = 19.9, 14.4 Hz, 13H). 
 
13C NMR (101 MHz, CDCl3): δ 159.92, 151.24, 150.62, 140.10, 139.66, 139.20, 
138.03, 136.77 , 134.30, 129.86, 129.43, 129.34, 128.54, 219.46, 76.91, 127.06, 
126.31, 125.33, 122.62, 119.76, 115.76, 115.18, 113.85 , 112.17, 110.07, 68.19, 
62.31, 50.49, 40.28 30.26, 29.41, 29.38, 29.32, 29.23, 28.98, 26.48, 26.04, 14.09, 
13.49. MS HRMS (TOF-APCI): m/z calculated for [M] + 1182.3359, found 
1182.3389, ∆ = -2.53 ppm 
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2.2.2.10 Synthesis of Compound 16 
 
 
 
 
Figure 23: Synthesis of Compound 16 
 
 
Both compound 8 (0.107 mmol, 20 mg) and compound 12 (0.083 mmol, 80 mg) 
were dissolved in a 10 mL round-bottomed flask containing 2 mL CHCl3 and 1 
mL EtOH. Saturated solution of Sodium ascorbate and CuSO4.5H2O were 
prepared in 1 mL water, separately. Then, 0.5 mL of CuSO4 and 0.5 mL of 
Sodium ascorbate solution were added to the flask, respectively. Catalytic amount 
of copper powder is added to this reaction mixture. The reaction was allowed to 
stirred for 8 h. Copper powder was eliminated by using filtration paper. Then, It 
was extracted with CHCl3 and water. Organic layer was dried with Na2SO4 and 
evaporated under reduced pressure. The product was purified by silica gel column 
chromatography using CHCl3. Fraction containing compound 16 was collected, 
then the solvent was removed under reduced pressure (64 mg, 66%). Extinction 
coefficient (Ɛ); 74,132 cm-1mol-1L in CHCl3. ʎ abs: 689 nm 
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1H NMR (400 MHz, CDCl3): δ 8.13 (d, J = 16.6 Hz, 1H), 8.01 (dt, J = 24.6, 12.2 
Hz, 1H), 7.69 – 7.57 (m, 3H), 7.46 (dt, J = 15.5, 7.7 Hz, 2H), 7.33 – 7.22 (m, 2H), 
7.21 – 7.13 (m, 4H), 7.09 – 7.01 (m, 3H), 7.01 – 6.90 (m, 6H), 6.86 (dd, J = 15.4, 
4.0 Hz, 1H), 5.21 (s, 2H), 4.37 (t, J = 7.2 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 3.87 
(d, J = 9.3 Hz, 6H), 1.92 (dd, J = 16.2, 9.5 Hz, 2H), 1.84 (dd, J = 14.4, 6.9 Hz, 
2H), 1.49 (dd, J = 10.3, 5.7 Hz, 8H), 1.35 (s, 11H).  
 
13C NMR (101 MHz, CDCl3): δ 160.78, 160.08, 148.23, 147.88, 142.00, 140.55, 
140.04, 138.68 , 137.40, 134.35, 132.64, 130.02, 129.37, 129.25, 128.40, 219.46, 
76.86, 127.01, 126.66, 124.20, 122.56, 121.08, 116.01, 115.76, 115.29, 114.33, 
110.46, 110.08, 68.22, 62.36, 55.39 , 50.48, 30.26, 29.39, 29.32, 29.23, 28.97, 
26.47, 26.04, 13.90. MS HRMS (TOF-APCI): m/z calculated for [M]+ 1156.2726, 
found 1156.2856, ∆ = 11.24 ppm 
 
 
2.3 Synthesis of Nanoparticles 
 
 
2.3.1 Synthesis of Fe3O4 Nanoparticles 
 
 
FeCl3  +  FeCl2
NH3.H2O
H20, 85 
oC
Fe3O4 Nanoparticles
 
 
Figure 24: Synthesis of Fe3O4 Nanoparticles 
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Magnetic nanoparticles were prepared according to the method already 
described117 with some modifications. 200 mL deionized water was bubbled with 
nitrogen gas at 85 oC for 10 minutes. Then, 3.225 g FeCl2.4H2O and 8.96 g 
FeCl3.6H2O were added to this reaction flask with vigorous stirring under nitrogen 
gas. 11.25 mL 25 % NH3.H2O was then added quickly to the solution. The 
alkaline solution was stirred for 20 min and was subsequently cooled to ambient 
temperature. The sediment was separated by magnetic decantation method and 
washed twice with deionized water and ethanol. Then, the precipitates were dried 
at lyophilizer for 24 h and black powder is stored at room temperature. 
 
 
 
2.3.2 Preparation of Water-Based Ferrofluid 
 
 
Fe3O4 Nanoparticles
Citric Acid, H20
NH3.H2O, 80 
oC
Fe3O4 Nanoparticles complexing with CA
 
 
Figure 25: Preparation of Water-Based Ferrofluid 
 
 
Stabilization of iron oxide nanoparticles with citrate groups were prepared118 by 
mixing 2 g of powder Fe3O4 nanoparticles in 65 mL of aqueous solution of citric 
acid (containing 2.5 g of CA) under vigorous stirring. By adding concentrated 
ammonia solution, the pH value was adjusted to 5.2 and heated to 80 oC for 90 
min. Then, the reaction was cooled to room temperature and pH value was 
increased to 10.1. To remove agglomerated nanoparticles, the suspension was 
centrifuged for 10 min at 6000 rpm. 
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2.3.3 Preparation of Fe3O4 @ SiO2 Nanoparticles 
 
 
 
TEOS, cat. NH4OH
Fe3O4@SiO2 NanoparticlesFe3O4 Nanoparticles complexing with CA
 
 
Figure 26: Preparation of Fe3O4 @ SiO2 Nanoparticles 
 
4 g of prepared water based magnetic ferrofluid was diluted with 120 mL water, 
and 480 mL ethanol. Then, 15 mL 25 %  NH3.H2O was added to this solution and 
this dispersion was homogenized by ultrasonic vibration in water bath for 30 min. 
Under mild mechanical stirring, 3 g tetraethyl orthosilicate was added slowly to 
the above dispersion. The reaction was allowed to proceed for 12 h. The 
Fe3O4@SiO2 nanoparticles were separated from reaction medium by centrifuging 
at 6000 rpm for 10 min. The product was washed with ethanol and water, and then 
vacuum dried under lyophilizer for 24 h. 
 
 
2.3.4 Preparation of Fe3O4 @ SiO2 – NH2 Nanoparticles 
 
APTES, 80 oC
Fe3O4@SiO2 Nanoparticles Fe3O4@SiO2-NH2 Nanoparticles
 
 
Figure 27: Preparation of Fe3O4 @ SiO2 – NH2 Nanoparticles 
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10 mg of Fe3O4@SiO2 nanoparticles were dispersed in 20 mL ethanol for 20 min 
via ultrasonication, and then 100 µL (3-aminopropyl) triethoxysilane was added to 
the reaction mixture. The reaction was allowed to proceed at 80 oC for 5 h. The 
amino modified Fe3O4@SiO2 nanoparticles were washed three times with ethanol, 
and then dried at lyophilizer for 24 h. 
 
 
2.3.5 Preparation of Fe3O4 @ SiO2 – Compound 13 
 
 
Fe3O4@SiO2-NH2 Nanoparticles
Compound 13
Isopropanol, THF, 30 0 C
13 13
13
13
13
MNPs - Compound 13
 
 
Figure 28: Preparation of Fe3O4 @ SiO2 – Compound 13 
 
Tetrahydrofuran was distilled to obtain the solvent in anhydrous form, and then 
both THF and isopropyl alcohol was degassed with N2 gas for 30 min. 25 mg of 
Fe3O4@SiO2-NH2  nanoparticles as a powder was added to 20 mL isopropanol and 
1 mL THF solvent mixture, and sonicated for 15 min. 1.6 mg of compound 13 
was added to this dispersion and continued sonication for 15 min. This reaction 
mixture was allowed to proceed at 30 oC under nitrogen at dark for 2 days. To 
separate MNPs – Compound 13 from reaction medium, it was centrifuged at 6000 
rpm for 10 min. It was washed with chloroform three times to remove any non-
binding compound 13. The solid was dried under lyophilizer for 24 h to give dark 
green solid. The content of compound 13 in MNPs was estimated to be about 
0.064 mg BODIPY/mg MNPs from the absorbance spectra of nonbinding 
compound 13. 
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2.3.6 Preparation of Fe3O4 @ SiO2 – Compound 14 
 
Fe3O4@SiO2-NH2 Nanoparticles
Compound 14
THF, 30 0 C
14
14
14
14
14
MNPs-Compound 14
 
 
Figure 29: Preparation of Fe3O4 @ SiO2 – Compound 14 
 
 
Tetrahydrofuran was distilled to obtain the solvent in anhydrous form, and then 
THF was degassed with N2 gas for 30 min. 20 mg of Fe3O4@SiO2-NH2 
nanoparticles as a powder was added to 20 mL THF, and sonicated for 15 min. 1.5 
mg of compound 14 was added to this dispersion and continued sonication for 15 
min. This reaction mixture was allowed to proceed at 30 oC under nitrogen at dark 
for 2 days. To separate MNPs – Compound 14 from reaction medium, it was 
centrifuged at 6000 rpm for 10 min. It was washed with chloroform three times to 
remove any non-binding compound 14. The solid was dried under lyophilizer for 
24 h to give black solid. The content of compound 14 in MNPs was estimated to 
be about 0.060 mg BODIPY/mg MNPs from the absorbance spectra of 
nonbinding compound 14. 
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2.3.7 Preparation of Fe3O4 @ SiO2 – Compound 15 
 
 
 
Fe3O4@SiO2-NH2 Nanoparticles
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 THF, 30 0 C
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Figure 30: Preparation of Fe3O4 @ SiO2 – Compound 15 
 
 
Tetrahydrofuran was distilled to obtain the solvent in anhydrous form, and then 
THF was degassed with N2 gas for 30 min. 20 mg of Fe3O4@SiO2-NH2 
nanoparticles as a powder was added to 20 mL THF, and sonicated for 15 min. 1.1 
mg of compound 15 was added to this dispersion and continued sonication for 15 
min. This reaction mixture was allowed to proceed at 30 oC under nitrogen at dark 
for 2 days. To separate MNPs – Compound 15 from reaction medium, it was 
centrifuged at 6000 rpm for 10 min. It was washed with chloroform three times to 
remove any non-binding compound 15. The solid was dried under lyophilizer for 
24 h to give black solid. The content of compound 15 in MNPs was estimated to 
be about 0.055 mg BODIPY/mg MNPs from the absorbance spectra of 
nonbinding compound 15. 
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2.3.8 Preparation of Fe3O4 @ SiO2 – Compound 16 
 
 
Fe3O4@SiO2-NH2 Nanoparticles
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Figure 31: Preparation of Fe3O4 @ SiO2 – Compound 16 
 
 
Isopropyl alcohol was degassed with N2 gas for 30 min. 20 mg of Fe3O4@SiO2-
NH2 nanoparticles as a powder was added to 20 mL isopropanol, and sonicated for 
15 min. 1.0 mg of compound 16 was added to this dispersion and continued 
sonication for 15 min. This reaction mixture was allowed to proceed at 30 oC 
under nitrogen at dark for 2 days. To separate MNPs – Compound 16 from 
reaction medium, it was centrifuged at 6000 rpm for 10 min. It was washed with 
chloroform three times to remove any non-binding compound 16. The solid was 
dried under lyophilizer for 24 h to give light green solid. The content of 
compound 16 in MNPs was estimated to be about 0.050 mg BODIPY/mg MNPs 
from the absorbance spectra of nonbinding compound 16. 
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CHAPTER 3 
 
 
 
RESULTS AND DISCUSSIONS 
 
 
 
3.1 SPION Based Nanoplatforms for Imaging and 
Therapy 
 
Colloidal MNPs have a wide range of interesting properties that make them 
practical for biological applications. They can be simply synthesized and 
functionalized, they are not expensive, they can be prepared colloidally stable, 
and they can be attached with biological molecules in a straightforward way. 
MNPs based on SPIONs offer lots of advantages for clinical purposes. Up to 
now, they have been utilized in humans for MRI imaging. In near future, they 
are likely to be also used for therapeutic issues78. Thus, in this study, SPIONs 
are synthesized as contrast agents. Then, they are coated with silica to provide 
colloidal and chemical stability. After coating the surface for silica, surface is 
functionalized with amine groups, which is needed for covalent modification of 
SPIONs with isothiocyanato terminated BODIPY derivatives.  
 
Photodynamic therapy (PDT) has already been recognized as a noninvasive 
technique for cancer treatment and promising results are obtained in clinical 
applications. PDT gives minimal damage to healthy surrounding tissue, when 
compared to other therapies such as chemo or radiotherapies.  One of the most 
important problems in clinical studies of PDT is related to penetration depth. 
Typical PSs are generally absorp lower wavelength of spectrum, where 
penetration is lower9,10. Therefore, we tried to synthesize four different 
BODIPY derivatives absorbing in near IR region. Singlet oxygen generation 
capabilities of these PSs are evaluated. In addition, since tracking of PSs in the 
body is very important in terms of clinics, we developed novel nanoplatforms 
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that combine MRI imaging and PDT. Four this purpose, four different 
BODIPY based PSs are attached covalently to silica coated SPIONs. We did 
not use any targeting agent since even in the nonexistence of specific targeting 
group, PSs tend accumulate at tumor loci because of enhanced permeation and 
retention effect. 
 
In this study, BODIPY is chosen because of its high extinction coefficient and 
high photostability. In addition, modification of core BODIPY is easy when 
compared to other PSs46. BODIPY core was synthesized through typical 
BODIPY reactions. In this research, 2,6 position of BODIPY core is decorated 
with bromines to increase spin-orbit coupling resulting efficacy in singlet 
oxygen production. Methyl groups in 3, 5 positions are acidic enough to 
participate in Knoevenagel condensation reactions. Via facile click reaction 
phenylic moiety possessing isothiocyanato group was linked to the BODIPY 
derivatives. Then, four different types synthesized PSs are attached to the 
amino modified SPIONs through the addition reaction between amino group 
and isothiocyanato. 
 
All the PSs synthesized were characterized using 1H, 13C NMR spectra and 
Mass spectrometry analysis. NMR spectra were measured using CDCl3 as 
solvent. All these data are given in appendices A and B. 
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3.2 Photophysical Measurements 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Normalized absorbance spectra of the synthesized molecules 13, 
14, 15 and 16 in CHCl3. 
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Maximum absorbance wavelength of photosensitizers 13, 14, 15, and 16 is 
determined to be 698, 755, 746 and 689 nm, respectively (Figure 32). All 
wavelengths correspond to near IR region is very appropriate for PDT 
applications because penetration depth of light of this wavelength is 
considerably high. 
 
 
 
 
 
 
 
 
 
Figure 33. Normalized emission spectra of the synthesized molecules 13, 14, 
15 and 16 in CHCl3. 
 
3.3 X-ray Diffraction (XRD) Analysis of Fe3O4 
Nanoparticles 
 
Spacing between adjacent lattice planes, d, was calculated by using Bragg’s 
law. Experimental d spacing obtained from X-ray diffraction patterns are 
reported in Table 4 and was found similar to the ASTM data cards of the 
Fe3O4.119 Based on the d spacing and the preparation method, it can be 
concluded that the iron oxide particles are mainly composed of the inverse 
cubic spinel structure of magnetite (Fe3O4). 
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Figure 34. XRD spectrum of the Fe3O4 nanoparticles, indicating the 
characteristic signals attributed to the crystal lattice of magnetite core. 
 
 
      Table 4: Summary data of experimental d (Å) spacings from X-ray patterns 
(d (exp.)) and from ASTM  data cards for iron oxide (d (Fe3O4) 
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3.4 Transmission Electron Microscopy (TEM) Analysis         
 
 
Figure 35. TEM image of the synthesized Fe3O4 nanoparticles. 
The sample was prepared by mounting a drop of dilute magnetic dispersion on 
carbon coated copper grid and drying at room temperature. Fig. 35 is TEM 
image of the synthesized Fe3O4 nanoparticles, which shows that most of the 
particles are quasi-spherical with a diameter ranging between of 5-10 nm. They 
have a tendency to aggregate because of magnetic dipole attractions. 
 
 
 
 
 
 
Figure 36. TEM image of the synthesized 
Fe3O4@SiO2 nanoparticles (a), (b), and (c). Histogram 
particle size distribution of Fe3O4@SiO2 nanoparticles 
with an average diameter of 124.5± 40.1 nm (d). The 
TEM images confirm the spherical shape of the 
Fe3O4@SiO2 (core/shell) structures of nanoparticles.  
 
a b c 
d 
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Figure 37. Energy dispersive X-ray (EDX) emission spectra of Fe3O4@SiO2 
nanoparticles. Strong Si peak and weak Fe peaks indicates the silica coating 
on magnetite nanoparticles.  
 
3.5 Vibrating Sample Magnetometer (VSM) Analysis of 
MNPs – Compound 13 
Magnetic particles less than about 25 nm shows superparamagnetism.120 Thus, 
the synthesized Fe3O4 nanoparticles are expected to exhibit 
superparamagnetism. To deduce the magnetic properties of magnetite 
nanoparticles after all modifications, the hysteresis loop of Fe3O4@SiO2–
Compound 13 nanoparticles was registered at room temperature and high field 
of 30 kOe using vibrating-sample magnetometer (shown in Fig. 38). The 
hysteresis loop demonstrated that there was no coercive force, thus featuring 
superparamagnetic behavior. The saturation magnetization of the 
Fe3O4@SiO2–Compound 13 nanoparticles was determined to be 2.93 emu/g 
(2.68 emu/g at field of 10 kOe) which is reasonable when compared to other 
both citrate and silica coated superparamagnetic nanoparticles.121
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Figure 38. VSM spectrum of the Fe3O4@SiO2-Compound 13 nanoparticles at 
room temperature, revealing a superparamagnetic behaviour with no coercive 
force in the hysteresis loop. 
 
3.6 MNPs – Bodipy Dye 16 in Ethanol 
 
       
 
 
 
                          
 
Figure 39. (a) Dispersion of bodipy dye 16 attached magnetic nanoparticles in 
ethanol, (b) and (c) 3 min after dispersion under influence of magnetic field (by 
magnet), (d) 7 min after dispersion under influence of magnetic field, clearness 
in ethanol indicates the successful attachment of bodipy dye 16 to MNPs.               
a b c d 
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3.7 X-ray Photoelectron Spectroscopy Surface Analysis 
for Amine Modification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. X-ray photon spectroscopy (XPS) spectra of Fe3O4 @SiO2–NH2 
nanoparticles presenting (a) a survey, and (b) N 1s spectra 
a 
b
a 
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To prove the surface modification with APTES, X-ray photoelectron spectra 
was obtained.  X- ray photoelectron spectroscopy (XPS) measurements were 
performed with Thermo Scientific, K-Alpha-Monochromated high-
performance XPS spectrometer with monochromatic Al K Alpha source. Wide 
scan surveys and specific region (N 1s) were measured with a step size of 1.0 
eV and 0.1 eV, respectively. XPS spectra were recorded in the CAE analyzer 
mode with a pass energy of 150 eV and 30 eV and an average of 2 and 30 
scans, respectively. The typical survey spectrum of Fe3O4@SiO2–NH2 
nanoparticles is presented in Fig. 40a. The peaks at binding energies 103.04 – 
110.08, 285.18 – 290.58, 399.41 – 406.08, 532.34 – 538. 58 eV are ascribed to 
Si2p, C1s, N1s, O1s electrons. A penetration depth should be high enough122 to 
detect iron in the underlying substrate; therefore, Fe2p3 and Fe3p electrons were 
not observed. The broad N1s peak which was deconvoluted into two spectral 
bands at 399.18, 401.11 eV in Fig. 40b is corresponding to the protonated and 
the unprotonated form present in APTES.123  
 
 3.8 Zeta Potential Measurements of MNPs 
 
Characterization of Fe3O4@SiO2-NH2 was conducted using zeta potential 
measurements at different pH values to determine the isoelectronic point (PI) 
of particles. The PI values can rise due to amine groups.121 The high value of 
PI for the modified magnetic nanoparticles showed that amine 
functionalization was achived. 
 
Zeta potential of MNPs with compounds 13, 14, 15, and 16 was determined 
in PBS buffer at pH 7 as -15.7 mV, -11.6 mV, -25.4 mV, and -29.2 mV, 
respectively. Other information related with instrument is given in the 
experimental details. 
 
 
 
  
66
 
 
 
*MNP: Fe3O4@SiO2 Nanoparticle 
*AMNP: Fe3O4@SiO2-NH2 Nanoparticle 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41.  Zeta potential of Fe3O4@SiO2 and Fe3O4@SiO2-NH2 nanoparticles 
as a function of pH. 
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3.9 Energy-Filtered Transmission Electron Microscopy 
(EFTEM) Images of MNPs – Compound 13 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
Figure 42.  Elemental maps in Fe3O4 @ SiO2 – Compound 13 nanoparticles 
from EFTEM images: (a) Boron map, (b) Bromine map, (c) Silicon map, (d) 
The RGB image created by superimposing the elemental EFTEM maps of B 
(green), Br (blue), and Si (pink). 
 
a b 
c d 
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3.10 Singlet Oxygen Generation Experiments 
Singlet oxygen generating capability of compound 13, 14, 15, and 16 was done 
using singlet oxygen trap molecule 1,3-diphenylisobenzofuran (DPBF) in 
dichloromethane. Singlet oxygen generating experiments for Fe3O4@SiO2 – 
Compound 13, 14, 15, 16 was conducted using singlet oxygen trap (DPBF) in 
isopropyl alcohol. Air saturated DCM and isopropanol was obtained by 
bubbling air for 15 minutes. Singlet oxygen can be monitored using 
photobleaching and subsequent decrease in absorbance of DPBF as shown in 
Figure 43.  
 
The absorbance of DPBF was adjusted around 1.0 in air saturated 
dichloromethane and isopropanol. Then, the photosensitizer was added to 
cuvette and photosentizer’s absorbance was adjusted around 0.2-0.3. After, 
taking some measurements in dark, we exposed the cuvette to 725 nm emitting 
3000 mCd lead light source for different time intervals for each solution. 725 
nm light was exposed from 12 cm cell distance for each solution containing 
compound 13, 14, 15, 16 and 4 cm cell distance for each solution containing 
Fe3O4@SiO2 – Compound 13, 14, 15, 16 and bare magnetic nanoparticles. 
 
 
 
 
 
 
 
Figure 43. Photobleaching of DPBF 
 
Control solution was prepared with bare nanoparticles (Fe3O4@SiO2 
nanoparticles without any attached bodipy derivatives). Absorbance was 
measured for several times after each irradiation. The graphics recorded are 
shown below; Figures 44 to 52. Compound 13 is the best singlet oxygen 
generator among the compounds 14, 15, and 16. 
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Figure 44. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 3.87 µM compound 13 in dichloromethane. Details are given in 
singlet oxygen measurements part. 
 
 
 
 
 
 
 
 
 
Figure 45. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 7.46 µM compound 13 attached to Fe3O4@SiO2 in isopropyl 
alcohol. Details are given in singlet oxygen measurements part. 
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Figure 46. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 4.59 µM compound 14 in dichloromethane. Details are given in 
singlet oxygen measurements part. 
 
 
 
 
 
 
 
 
 
 
Figure 47. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 8.71 µM compound 14 attached to Fe3O4@SiO2 in isopropyl 
alcohol. Details are given in singlet oxygen measurements part. 
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Figure 48. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 4.81  µM compound 15 in dichloromethane. Details are given in 
singlet oxygen measurements part. 
 
 
 
 
 
 
 
 
 
Figure 49. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 12.6 µM compound 15 attached to Fe3O4@SiO2 in isopropyl 
alcohol. Details are given in singlet oxygen measurements part. 
 
350 375 400 425 450
0,2
0,4
0,6
0,8
1,0
1,2
 dark
 hν  (1 min)
 hν   (2 min)
 hν   (3 min)
 hν   (4 min)
 hν   (5 min)
 hν   (6 min)
Compound 15
Ab
so
rb
an
c
e(a
.
u
.
)
Wavelength(nm)
350 375 400 425 450
0,0
0,2
0,4
0,6
0,8
1,0
 dark
 hν (10 min )
 hν (20 min )
 hν (30 min )
 hν (40 min )
 hν (50 min )
 hν (60 min )
Ab
so
rb
an
ce
(a.
u.
)
Wavelength(nm)
NP+15
15
15
15
15
15
ʎ abs: 746 
nm 
N
B
N
O
FF
Br Br
N
N
N
O
NCS
8
N(CH3)2(H3C)2N
  
72
 
 
 
 
 
 
 
 
Figure 50. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 3.37 µM compound 16 in dichloromethane. Details are given in 
singlet oxygen measurements part. 
 
 
 
 
 
 
 
 
 
Figure 51. Decrease in absorbance spectrum of trap molecule DBPF in the 
presence of 8.66 µM compound 16 attached to Fe3O4@SiO2 in isopropyl 
alcohol. Details are given in singlet oxygen measurements part. 
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Figure 52. Control singlet oxygen generation experiment. There is no decrease 
in absorbance spectrum of trap molecule DBPF in the presence of 0.03 mg 
Fe3O4@SiO2 nanoparticle in 1.3 ml isopropyl alcohol after six times light 
irradiation with 1 min interval. Details are given in singlet oxygen 
measurements part. 
 
 
 
Figure 53. Snapshot of 725 nm emitting 3000 mCd lead light source taken 
Overture software by Ocean Optics. 
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CHAPTER 4 
 
 
 
CONCLUSION 
 
In this research, four different types of BODIPY-based photodynamic therapy 
agents synthesized and characterized by various characterization techniques. 
These PSs were then covalently attached to MRI active, biocompatible and 
nontoxic silica coated SPIONs. By this way, a multidisciplinary approach was 
followed to create novel theranostic nanoparticles for both MRI imaging and 
photodynamic therapy. Although we did not conduct in vivo studies for 
SPIONs, it is well known that iron oxide nanoparticles show great potential for 
clinical applications due to their high biocompatibility. In addition, besides 
being a MRI contrast reagent, iron oxide NPs show therapeutic termal effect 
(hyperthermia) under influence of magnetic field. Moreover, by the application 
of an external magnetic field gradient, these novel drug carrier nano platforms 
can be targeted directly to tumor loci. Therefore, further research is needed to 
improve these therapeutic nanoplatforms for clinical applications. 
 
Physical properties of nanoparticles are characterized well using TEM, EDAX, 
XRD, XPS, Zeta sizer, and magnetometry. Generation of singlet oxygen 
capabilities are followed by absorbance spectrum. Singlet oxygen generation 
experiments show that all the compounds 13, 14, 15, 16 are an effective singlet 
oxygen generator in micro molar concentrations upon irradiation with LED. 
Moreover, they still preserve their ability to generate singlet oxygen after 
attachment to the nanoparticles. Therefore, it is shown that these modified 
core-shell nanoparticles shows potential as a delivery vehicles of PSs for the 
use in diagnosis and therapy. 
 75
REFERENCES 
 
 
 
 
1. Hopper, C. Lancet Oncol. ,  2000, 1, 212. 
 
2. Konan, Y.N.; Gurny, R.; Alle´mann, E. Photochem. Photobiol. B: Biology 
66, 2002, 89  
 
3. Levy, G.; Obochi, M. Photochem. Photobiol., 1996, 64, 737 
 
4. Kubler, A.C. Med. Laser Appl., 2005, 20, 37. 
 
5. Mitra, A.; Stables, G.I. Photodiag. Photodyn. Ther., 2006, 3, 116 
 
6. Schuitmaker, ; Bass, P.; Van Leengoed, H.L.L.M.; Van Der Meulen, F.W.; 
Star, W.M.; Zandwijk, N. Photochem. Photobiol.: B. Biol., 1996, 34, 3. 
 
7. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Photodiag. Photodyn. 
Ther., 2005, 2, 1. 
 
8. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W., 
Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; 
Korbelik, M.; Moan, ; Mroz, P.; Nowis, D.; Piette, ; Wilson, B.C.; Golab,  
CA Cancer J Clin., 2011, 61, 250. 
 
9. Lovell, F.; Liu.B, T.W.; Chen, ; Zheng, G. Chem. Rev. 2010, 110, 2839. 
 
10. Castano, A.P.; Demidova, T.N.; Hamblin. Photodiag. Photodyn. Ther., 
2004, 1, 279. 
 
11.  Juzeniene, A.; Moan,  Photodiag. Photodyn. Ther., 2007, 4, 3. 
 
12. Robertson, C.A.; Evans, D.H.; Abrahamse, H. Photochem. Photobiol. B: 
Biology, 2009, 96, 1. 
 
13. Ochsner, M. Photochem. Photobiol.: B. Biol., 1996, 32,  3. 
 
14. Bilski, P.; Motten, A. G.; Bilska, M.; Chignell, C.F. Photochem Photobiol. 
1993, 58, 8. 
 
15. Ma J, Jiang L. Free Radic Res, 2001, 35, 767. 
 
16. Foote CS. Science, 1968, 162, 963. 
 
17. Plaetzer, K.; Krammer, B.; Berlanda, ; Berr, F.; Kiesslich, T. Laser. Med. 
Sci. 2008, 1, 1. 
 76
 
18. Detty, M.R.; Gibson, S.L.; Wagner, S. Journal of Medicinal Chemistry, 
2004,  47, 16. 
 
19. Allison R.R.; Downie G.H.; Cuenca, R.; Hu, X.H.; Childs,  C.; Sibata, 
C.H. Photodiag. Photodynam.Ther. 2004, 1, 27. 
 
20. Sharman, W. M.; Allen, C. M.; Van Lier,  E. Drug Discovery Today 1999, 
4, 507. 
 
21. Juzeniene, A.; Nielsen, K.P.; Moan, Environ Pathol Toxicol Oncol., 2006, 
25, 7. 
 
22. Gorman, A.; Killoran, ; O’Shea, C.; Kenna, T.; Gallagher, M. W.; O’Shea, 
D. F.  J. Am. Chem. Soc., 2004, 126, 10619. 
 
23. Turro, N.  In Modern Molecular Photochemistry; University Science 
Books: Sausalito, CA, 1991, 191. 
 
24. Lower, S.K.; El-Sayed, M.A. Chem. Rev., 1966, 66, 199. 
 
25. Svaasand, LO. Prog Clin Biol Res 1984, 170, 91. 
 
26. Wilson, B.C.; Jeeves, W.P.; Lowe, D.M. Photochem Photobiol, 1985, 42, 
153. 
 
27. Henderson, B.W.; Busch, T.M.; Snyder, W. Lasers Surg Med., 2006, 38, 
489. 
 
28. Brancaleon, L.; Moseley, H. Lasers Med Sci., 2002, 17, 173., 
 
29. Szeimies, R.M.; Morton, C.A.; Sidoroff, A.; Braathen, L.R. Acta Derm 
Venereol, 2005, 85, 483. 
 
30. Wilson, B.C.; Patterson, M.S. Phys Med Biol., 2008, 53, R61. 
 
31.  Lukšienė, Ž.MEDICINA, 2003, 39 tomas, Nr. 12. 
 
32. Kalka, K.; Merk, H.; Mukhtar, H. J Am Acad Dermatol, 2000, 42(3), 389. 
 
33. Roland, C.L.; Harken, A.H.;  Sarr, M.G.; Barnett, C.C.  Surg., 2007, 141, 
705. 
 
34. Buytaert, E.; Dewaele, M.; Agostinis, P. Biochem. Biophys. Acta, 2007, 
1776, 86. 
 
35. Davids, L.M.; Kleemann, B.; Kacerovska, D.; Pizinger, K.; Kidson, S.H.  
Photochem. Photobiol.: B. Biol., 2008, 91, 67. 
 77
 
36. Pazos, M:D:C.; Nader, H.B. Braz.  Med. Biol. Res., 2007, 40, 1025. 
 
37. Nowis, D.; Stoklosa, T.; Legat, M.; Issat, T.; Jakobisiak, M.; Golab,  
Photodiag. Photodyn. Ther., 2005, 2, 283. 
 
38. Wieman T.; Fingar, V.H. SPIE Conf Proc, 1989, 106, 11. 
 
39. M.P. Zhen-hui Peng, M.P.; Xiao, S.; Ren, ; Liu, Y.; Li, X.; Li, Z.,  Nanjing 
Med. Univ., 2008, 22, 18. 
 
40. Berg, K.; Bommer, C.; Moan,  Cancer Letters, 1989, 44, 7. 
 
41. Jori, G.; Beltramini, M.; Reddi, E.; Salvato, B.; Pagnan, A.; Ziron, L. 
Cancer Letters, 1984, 26, 291. 
 
42. Kessel, D.; Thompson, P.; Saatio, K.; Nanturi, K.D.Photochem Photobiol, 
1987, 45, 787. 
 
43. Huang, Z. Technol Cancer Res Treat., 2005, 4(3), 283. 
 
44. Moser, JG. Definitions and General Properties of 2nd & 3rd Generation 
Photosensitizers. In: Moser, JG., editor. Photodynamic Tumor Therapy-
2nd & 3rd Generation Photosensitizers. Harwood Academic Publishers; 
London: 1997. p. 3-8. 
 
45. Berenbaum, M.C., Chevretton, E.B. Lasers Med Sci, 1993, 8, 235. 
 
46. Loudet, A.; Burgess, K. Chem. Rev., 2007, 107, 4891. 
 
47. Atilgan, S.; Ekmekci, Z.; Dogan, A. L.; Guc, D.; Akkaya, E. U. Chem. 
            Commun., 2006, 4398. 
 
48. Kral, V.; Davis, ; Andrievsky, A. J Med Chem. 2002, 45, 1073. 
 
49. Szeimies, R.M.; Karrer, S.; Abels, C. J Photochem Photobiol B, 1996, 34, 
67. 
 
50. Bellnier, D. A.; Greco, W. R.; Loewen, G. M.; Nava, H.; Oseroff, A. R.; 
Pandey, R. K.; Tsuchida, T.; Dougherty, T.  Cancer Res., 2003, 63, 1806. 
 
51. Kato,  Photochem. Photobiol., B. 1998, 42, 96. 
 
52. Jichlinski, P.; Leisinger, H.- Urol. Res. 2001, 29, 396. 
 
53. Moesta, K. T.; Schlag, P.; Douglas, H. O., Jr.; Mang, T. S. Lasers Surg. 
Med., 1995, 16, 84. 
 
 78
54. Nathan, T. R.; Whitelaw, D. E.; Chang, S. C.; Lees, W. R.; Ripley, P. M.; 
Payne, H.; Jones, L.; Parkinson, M. C.; Emberton, M.; Gilliam, A. R.; 
Mundy, A. R.; Bown, S. G.  Urol., 2002, 168, 1427. 
 
55. Baas, P.; Saarnak, A.; Oppelaar, H.; Neering, H.; Stewart, F. A. Br.  
Dermatol., 2001, 145, 75. 
 
56.  Loman,  A.; Morton, C. A. Expert Opin. Biol. Ther. 2002, 2, 45. 
 
57. Rechtman, E.; Ciulla, T. A.; Criswell, M. H.; Pollack, A.; Harris, A. 
Expert Opin. Pharmacother. 2002, 3, 931. 
 
58. Wainwright, M. Antimicrob. Agents, 2003, 21, 510. 
 
59. Wilson BC. Photonic and non-photonic based nanoparticles in cancer 
imaging and therapeutics. In: Dubowski J, Tanev S, eds. Photon-Based 
Nanoscience and Nanobiotechnology. Dordrecht, the Netherlands: 
Springer; 2006, 121. 
 
60. Richter A.M.; Waterfield, E.; Jain, A.K.; Canaan, A.; Allison, B.A.; Levy, 
G. Photochem Photobiol., 1993, 57, 1000. 
 
61. Chatterjee, D.K.; Fong, L.S.; Zhang, Y. Adv Drug Deliv Rev. 2008, 60, 
1627. 
 
62. Rai, P.; Chang, S.K.; Mai, Z.; Neuman, D.; Hasan, T. Proc SPIE., 2009, 
7380, 73801. 
 
63. Chen, ; Stefflova, K.; Niedre, M.J Am Chem Soc., 2004, 126, 11450. 
 
64. Zheng, G.; Chen, ; Stefflova, K.; Jarvi, M.; Li, H.; Wilson, B.C. Proc Natl 
Acad Sci U S A. 2007, 104, 8989. 
 
65. Ozlem S.; Akkaya E. U.  J. Am. Chem. Soc., 2009, 131, 48. 
 
66. Starkey, R.; Rebane, A.K.; Drobizhev, M.A. Clin Cancer Res., 2008, 14, 
6564. 
 
67. Collins, H.A.; Khurana, M.; Moriyama, E.H. Nature Photonics., 2008, 2, 
420.  
 
68. Brown, S.B.; Brown, E.A.; Walker, I. Lancet Oncol., 2004, 5, 497. 
 
69. Koo, Y. E.; Reddy, G. R.; Bhojani, M.; Schneider, R.; Philbert, M. A.; 
Rehemtulla, A.; Ross, B. D.; Kopelman, R. Adv. Drug Delivery Rev., 
2006, 58 (14), 1556. 
 
 79
70. Bhojani, M. S.; Reddy, G. R.; Koo, Y.; Philbert, M.; Kopelman, R.; 
Rehemtulla, A.; Ross, B. D. Multifunctional nanoparticles for targeted 
imaging and therapy. In Cancer Nanotechnology; Nalwa, H. S., Wester, T. 
, Eds., American Scientific Publishers., 2007, 81. 
 
71. Moghimi, S. M.; Hunter, A. C.; Murray,  C. FASEB J,. 2005, 19 (3), 311. 
 
72. Gao, X.; Cui, Y.; Levenson, R.M.; Chung, L.W.K.; Nie, S. Nat. 
Biotechnol., 2004, 22, 969. 
 
73. Lodhia, Biomed Imaging Interv J, 2010, 6(2), e12 
 
74. Ferrari, M. Nat. Rev. Cancer, 2005, 5, 161. 
 
75. De, M.; Ghosh, P.S.; Rotello, V.M. Adv. Mater., 2008, 20, 4225. 
 
76. Kelkar, S.S.; Reineke, T.M. Bioconjugate Chem., 2011, 22, 1879. 
 
77. Bhojani, M.S.; Van Dort, M.; Rehemtulla, A.; Ross, B.D. Moleculer 
Pharmaceutics., 2010, 7 (6), 1921. 
 
78. Sonvico, F.; Mornet, S.; Vasseur, S.; Dubernet, C.; Jaillard, D.; 
Degrouard, ; Hoebeke, ; Duguet, E.; Colombo, P.; Couvreur, P. 
Bioconjugate Chem., 2005, 16 (5), 1181. 
 
79. Liong, M.; Lu, ; Kovochich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; 
Tamanoi, F.; Zink,  I. ACS Nano, 2008, 2 (5), 889. 
 
80. Medarova, Z.; Kumar, M.; Ng, S. W.; Yang, ; Barteneva, N.; Evgenov, N. 
V.; Petkova, V.; Moore, A. Transplantation, 2008, 86 (9), 1170. 
 
81. Kumar, A.; Jena, P. K.; Behera, S.; Lockey, R. F.; Mohapatra, S.; 
Mohapatra, S. Nanomedicine, 2010, 6 (1), 64. 
 
82. McCarthy,  R.; Weissleder, R. Adv Drug Delivery Rev 2008, 60 (11), 
1241. 
 
83. Blanco, E.; Kessinger, C. W.; Sumer, B. D.; Gao,  Exp. Biol. Med. 
(Maywood) 2009, 234 (2), 123. 
 
84. Guo, R.; Zhang, L.; Qian, H.; Li, R.; Jiang, X.; Liu, B. Langmuir , 26 (8), 
5428. 
 
85. Bhaskar, S.; Tian, F.; Stoeger, T.; Kreyling, W.; de la Fuente,  M.; Grazu, 
V.; Borm, P.; Estrada, G.; Ntziachristos, V.; Razansky, D. Part. Fibre 
Toxicol., 2010, 7, 3. 
 
 80
86. Gindy, M. E.; Prud’homme, R. K. Expert Opin. Drug Delivery 2009, 6 (8), 
865. 
 
87. Masotti, A. Recent Pat. Nanotechnol., 2010, 4 (1), 53. 
 
88. O'Brien, M. E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, 
A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P.; Orlandi, F.; 
Mellars, L.; Alland, L.; Tendler, C. Ann Oncol., 2004, 15 (3), 440. 
 
89. Chen, W.; Bardhan, R.; Bartels, M.; Perez-Torres, C.; Pautler, R. G.; 
Halas, N. ; Joshi, A. Mol. Cancer Ther., 2010, 9 (4), 1028. 
 
90. Lu, A.H.; Salabas, E.L.; Schüth F. Angew. Chem. Int. Ed., 2007, 46, 1222. 
 
91. Morales, M.P.; Verdaguer, S.V.; Montero, M.I.; Serna, C.; Roig, A.; 
Casas, L.I.; Martinez, B.; Sandiumenge, F. Chem.Mater., 1999, 11, 3058. 
 
92. H. Martin, Magnetism in solids, The M.I.T press, Cambridge, 
Massachussets, 1967. 
 
93. D. Jiles, Introduction to magnetism and magnetic materials, Chapman & 
Hall, 1991. 
 
94. Colombo, M.; Romero, S.C.; Casula, M.F.; Gutie´rrez, L.; Morales, M.; 
Böhm, I.B.; Heverhagen, T.; Prosperi, D.; Parak, W. Chem. Soc. Rev., 
2012, 41, 4306. 
 
95. Jun, Y.W.; Seo, W.; Cheon,  Acc. Chem. Res., 2008, 41,179. 
 
96. Koseoglu, Y.  Magn. Magn. Mater., 2006, 300, 327. 
 
97. Jun, Y.W.; Lee, H.; Cheon, Angew. Chem. Int. Ed., 2008, 47, 5122. 
 
98. Bellin, M.F. Eur.  Radiol., 2006, 60, 314. 
 
99. Harisinghani, M.G.; Jhaveri, K.S.; Weissleder, R.; Schima, W.; Saini, S.; 
Hahn, P.F.; Mueller, P.R. Clin. Radiol., 2001, 56, 714.  
 
100. Sandhu, A.; Handa, H.; Abe, B. Nanotechnology, 2010, 21, 
442001. 
 
101. Jun, Y.W.; Huh, Y.M.; Choi, S. J Am Chem Soc., 2005, 127(16), 
5732. 
 
102. Gupta, A.K.; Gupta, M. Biomaterials, 2005, 26 (18), 3995. 
 
 
 
 81
103. Jun, Y.W.; Lee, H.; Cheon,  Nanoparticle Contrast Agents for 
Molecular Magnetic Resonance Imaging. in: Mirkin, C.A. Niemeyer MC 
eds. Nanobiotechnology II: More Concepts and Applications. Weinheim: 
Wiley-VCH, 2007. 
 
104. Laurent, S.; Forge, D.; Port, M.  Chem Rev., 2008, 108(6), 2064. 
 
105. Lawaczeck, R.D.; Menzel, M.; Pietsch, H. Appl Organomet Chem, 
2004, 18, 506. 
 
106. Bee, A.; Massart, R.; Neveu, S. J Magn and Magn Mat, 1995, 149, 
6. 
 
107. Burda, C.; Chen, X.; Narayanan, R. Chem Rev., 2005,105(4), 1025. 
 
108. Pedro T, P MM, Sabino VV et al. Synthesis, Properties and 
Biomedical Applications of Magnetic Nanoparticles. in: Buschow KHJ ed. 
Handbook of Magnetic Materials. The Netherlands: Elsevier B V, 2006. 
 
109. Sun, S.; Zeng, H. J Am Chem Soc., 2002, 124 (28), 8204. 
 
110. Hyeon, T.; Lee, S.S.; Park, J Am Chem Soc., 2001, 123 (51), 
12798. 
 
111. Lopez-Perez A.; Lopez-Quintela M.A.; Mira,  IEEE Trans Magn, 
1997,  33 (5), 4359. 
 
112. Degiorgio V. Physics of amphiphiles: micelles, vesicles and 
microemulsions. Amsterdam: 1985. 
 
113. Wan, S.; Huang, ; Guo, M. J Biomed Mater Res A, 2007, 80 (4), 
946. 
 
114. Stöber, W.; Fink, A.; Bohn, E. J Colloid and Interface Sci., 1968, 
26 (1), 62. 
 
115.  Li, H.; Cheng, F.;Duft, A.M.; Adronov, A.  J. Am. Chem. Soc., 
2005, 127 (41), 14518. 
 
116. Chaskar, A.C.; Bandgar, B.P.; Modhave, R.K.; Patil A.B. Synthetic 
Communications: An International Journal for Rapid Communication of 
Synthetic Organic Chemistry, 39, 6, 992. 
 
117. Xu, H.; Wan, X.; Shen, Y.Y.; Xu, S.; Feng, Y.S. Org. Lett., 2012, 
14 (5), 1210. 
 
118. Kralj, S.; Drofenik, M.; Makovec, D. Nanopart Res., 2011, 13, 
2829. 
 82
 
119. Deng, Y.H.; Wang, C.C.; Hu, H.; Yang, W.L.; Fu, S.K. Colloids 
and Surfaces A: Physicochem. Eng. Aspects, 262, 2005, 87. 
 
120. Lee, ; Isobe, T.; Senna, M. Colloid Interface Sci. 177, 1996, 490. 
 
121. Mohammad-Beigi, H.; Yaghmaei, S.; Roostaazad, R.; Bardania, 
H.; Arpanaei, A. Physica, 2011, E44, 618. 
 
122. Liu, Q.; Xu, Z.; Finch, A.; Egerton, R. Chem. Mater., 1998, 10 
(12), 3936. 
 
123. Koh, I.; Wang, X.; Varughese, B.; Isaacs,L.; Ehrman S.H.; English, 
D.S. Phys. Chem. B, 2006, 110, 1553. 
 
 83
O
CHO
N3
8
3
APPENDIX A 
 
 
 
MASS SPECTRA 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54. APCI – HRMS of Compound 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. APCI – HRMS of Compound 3 
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Figure 56. APCI – HRMS of Compound 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57. APCI – HRMS of Compound 5 
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Figure 58. APCI – HRMS of Compound 7 
 
 
 
 
 
 
 
Figure 59. APCI – HRMS of Compound 8 
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Figure 60. APCI – HRMS of Compound 9 
 
 
 
 
 
 
Figure 61. APCI – HRMS of Compound 10 
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Figure 62. APCI – HRMS of Compound 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63. APCI – HRMS of Compound 12 
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Figure 64. APCI – HRMS of Compound 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 65. APCI – HRMS of Compound 14 
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Figure 66. APCI – HRMS of Compound 15 
 
 
 
                                                                                                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 67. APCI – HRMS of Compound 16 
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